

From Ludwig Institute for Cancer Research Ltd  
and Department of Medical Biochemistry and Biophysics,  
Karolinska Institutet, Stockholm, Sweden

# **Vascular Metabolomics —**

## **gene regulation and role of VEGF-B in tissue fatty acid uptake**

**Xun Wang**



**Karolinska  
Institutet**

Stockholm 2012

All previously published papers were reproduced with permission from the publisher.

Published by Karolinska Institutet. Printed by Larserics Digital Print AB

© Xun Wang, 2012

ISBN 978-91-7457-919-2

## **To my parents and the Universe**

Nearly 14 billion years ago, it all started with the Big Bang...

About the cover picture: NGC5897 is a globular cluster of stars, which symbolizes the “messy” metabolism regulatory networks. This deep-sky object, about 40,000 light-years away, is located in the constellation Libra, which symbolizes the metabolic balance elucidated in Paper II.

Copyright Daniel Verschatse - Observatorio Antilhue - Chile

## 科普综述

地球上的生命有着 36 亿年漫长的进化史。大约 10 亿年前，多个特化的系统逐渐衍生出来，这极大的推动了生物从单细胞到复杂多细胞结构的进化。其中之一就是存在于现代高等生物体内的血液循环系统。血液循环系统（依托血管和血液）向机体各部分输送氧气和营养，同时带走二氧化碳和代谢废物。血管中最靠近血液的一层细胞称为血管内皮，是血液循环系统中最重要的一部分之一。有一族蛋白分子，称为血管内皮生长因子。它们负责控制最初胚胎血管的形成和发育，以及维持成年动物体内血管的正常功能。1996 年，我们的实验室发现了血管内皮生长因子 B，这里简称为“B”。蛋白因子 B 就是本论文的研究对象。

本论文包含两篇文章，第一篇阐述了 B 在体内的生理功能，第二篇则阐述了 B 在体内是如何按需调节的。与同家族其它成员不同，B 不控制血管生长，而且完全缺乏 B 的小鼠没有任何明显的生理缺陷和异常。因此，在发现 B 后相当长的一段时间内，其生理作用和调控机制均未获得阐释。众所周知，细胞中的线粒体负责生产能量。我们在 2005 年意外发现 B 和线粒体存在高度的关联，这是其他任何生长因子都不具备的。有鉴于此，我们进而阐明了上述关于 B 生物学意义的最重要的两个问题。

线粒体主要通过“燃烧”两种物质来产生能量，分别是葡萄糖和脂肪酸。已知葡萄糖在体内主要通过胰岛素来进行调节，所以我们假设 B 应当负责脂肪酸的转运。经过一系列的实验，果然如此，问题一得到解答。问题二：既然 B 和线粒体关联度极高，那么 B 的调节应该和线粒体的调节类似。已知有一种调节线粒体功能的蛋白简称为“P”，经过一系列的实验，P 果然可以调节 B。两个基本问题都回答了，那么 B 在体内是如何发挥作用的呢？以肌肉为例：肌肉细胞经过锻炼后，需要更多能量，于是 P 被激活。它一方面促进线粒体数量的增加，一方面促进肌肉细胞分泌 B。B 虽然不能控制血管的生长，但可以指导血管把更多的脂肪酸从血液转运到肌肉细胞里。既增加了燃料（脂肪酸），又增强了引擎（线粒体），引擎得以加速运转，就产生了更多能量。这样，肌肉细胞有能力更快更多地产生能量，为下一次运动做好准备。

那我们的科研意义何在呢？目前，尤其是在中国等一些发展中国家，糖尿病已经发展成为一种常见病。营养过剩再加上运动匮乏，往往导致肥胖；长期过度肥胖极易罹患 II 型糖尿病。近十几年的研究表明，过多摄取碳水化合物（包括饮食中的糖，以及存在于面食和米饭中的淀粉等）并不是 II 型糖尿病的根本致病原因，这与人们通常的理解大相径庭。事实上，肥胖本身也不是根本病因。真正的原因是脂肪去错了地方：摄入脂肪等能量物质过多（多余的糖、淀粉等在体内也会转化成脂肪），会超过身体脂肪组织的存储能力，这就导致过多的脂肪进入肝、肌肉、心脏等组织，这就是“脂肪溢出假说”。这些组织中脂肪含量太多，会严重影响组织对葡萄糖的吸收，进而导致葡萄糖滞留在血液中，血糖也就升高了。

我们的研究对象 B，专门负责脂肪酸在肌肉和心脏等组织中的转运。如果能够阻断 B，上述组织就不会过量吸收脂肪酸，而会重新增加对葡萄糖的吸收，这样 II 型糖尿病的症状就会得到改善。实际上，本论文及本实验室最近发表于 Nature 的另一篇文章，已经通过多种方法证实了这一点。在大鼠或小鼠上的动物实验证明，即使过量进食高脂肪食物，缺乏运动，只要阻断 B 的作用，它们也会“胖并快乐着”，所有与 II 型糖尿病相关的症状都得到了显著的改善。总之，我们的研究成果为开发高效抗糖尿病药物提供了全新的思路。

## ABSTRACT

Vascular endothelial growth factor B (VEGF-B) belongs to the VEGF family, which constitutes of five mammalian members. VEGFs exert pivotal roles in the formation, development and maintenance of the vascular and lymphatic vessels. Unlike VEGF-A, the first VEGF discovered and a close homologue, VEGF-B is poorly angiogenic in most tissues and not regulated by hypoxia. Gene regulation and physiological function of VEGF-B remained obscure for more than a decade after its discovery.

We identified an unexpected high correlation of expression of *Vegfb* with a large cluster of nuclear-encoded mitochondrial genes. This high correlation is not shared by any other VEGF gene. Based on this finding, we were able to answer two fundamental questions in VEGF-B biology in this thesis work: gene regulation and role of VEGF-B.

In Paper I, we identified an unexpected role of VEGF-B in tissue fatty acid (FA) uptake. VEGF-B induces endothelial FA uptake through upregulation of two fatty acid transporter proteins (FATPs), namely FATP3 and FATP4. This regulation is dependent on the two known receptors for VEGF-B, VEGF receptor 1 (VEGFR1) and neuropilin 1 (NRP1), and it is unique among the three VEGFR1 ligands. Genetically modified mouse models that are deficient in VEGF-B signaling showed reduced lipid accumulation in peripheral tissues. In *Vegfb* knockout mice, FA uptake capacity in heart, skeletal muscle and brown adipose tissue was reduced. The resulted excess FA was diverted to white adipose tissue for storage. As a consequence, the glucose uptake capacity in the heart was drastically increased in *Vegfb* knockout mice.

In Paper II, we demonstrated that *Vegfb* is regulated by peroxisome proliferator activated receptor coactivator 1 $\alpha$  (PGC-1 $\alpha$ ) through coactivation of estrogen-related receptor  $\alpha$  (ERR $\alpha$ ). *Vegfb* was upregulated in parallel with *Pgc1 $\alpha$*  and mitochondrial genes upon nitric oxide simulation and serum deprivation in cells. ERR $\alpha$ , together with PGC-1 $\alpha$ , strongly activated the *Vegfb* promoter in luciferase assay. It is known that muscle creatine kinase PGC-1 $\alpha$  transgenic (MCK-PGC-1 $\alpha$  TG) mice become insulin resistant on a high-fat-diet (HFD). *Vegfb* deficiency in HFD-fed MCK-PGC-1 $\alpha$  TG mice greatly improved insulin sensitivity as well as other metabolic parameters. This improvement may be attributed to the reduction in muscular lipid accumulation.

PGC-1 $\alpha$  and ERR $\alpha$  are known major regulators of mitochondrial biogenesis. In this thesis, we have elucidated that they also regulate VEGF-B expression and hence endothelial FA uptake in parallel. The two pathways are tightly coordinated to maintain a balance of FA  $\beta$ -oxidation and lipid homeostasis in the body. These findings have opened up new horizons for finding therapeutic targets in treating metabolic disorders such as type 2 diabetes.

## LIST OF PUBLICATIONS

- I. Hagberg CE, Falkevall A, **Wang X**, Larsson E, Huusko J, Nilsson I, van Meeteren LA, Samén E, Lu L, Vanwildemeersch M, Klar J, Genove G, Pietras K, Stone-Elander S, Claesson-Welsh L, Ylä-Herttuala S, Lindahl P, Eriksson U. Vascular endothelial growth factor B controls endothelial fatty acid uptake. *Nature*. 2010 Apr 8; 464(7290):917-21.
  
- II. **Xun Wang**, Annika Mehlem, Annelie Falkevall, Carolina Hagberg and Ulf Eriksson. VEGF-B mediates high-fat-diet-induced insulin resistance in PGC-1 $\alpha$  overexpressing muscle.  
*Manuscript*.

# CONTENTS

1	Introduction .....	1
1.1	VEGFs and their receptors.....	1
1.2	VEGF-B.....	6
2	Aims.....	8
3	Paper I: VEGF-B controls endothelial FA uptake .....	9
3.1	Current view and hypotheses of FA transport .....	9
3.2	Post-angiogenesis: the endothelial barrier.....	9
3.3	Physiological role of VEGF-B.....	10
3.4	Conclusion.....	12
4	Paper II: <i>Vegfb</i> is regulated by PGC-1 $\alpha$ .....	13
4.1	Gene regulation of VEGFs.....	13
4.2	PGC-1 $\alpha$ regulates <i>Vegfb</i> and mitochondrial biogenesis.....	13
4.3	VEGF-B mediates insulin resistance in MCK-PGC-1 $\alpha$ TG mice .....	16
4.4	Conclusion.....	18
5	Future perspectives .....	19
5.1	Role of VEGF-B in other contexts .....	19
5.2	The significance of our research .....	21
6	Acknowledgements .....	25
7	References .....	30

## LIST OF ABBREVIATIONS

BAT	brown adipose tissue
<sup>14</sup> C-OA	<sup>14</sup> C-labeled oleic acid
cDNA	complementary deoxyribonucleic acid
<i>Cyts</i>	cytochrome c, somatic
ERR $\alpha$	estrogen-related receptor $\alpha$
FA	fatty acid
FATP	fatty acid transporter protein
[ <sup>18</sup> F]FDG	<sup>18</sup> F-labeled deoxyglucose
HFD	high-fat diet
HIF-1 $\alpha$	Hypoxia-inducible factor 1 $\alpha$
HSPG	heparan sulfate proteoglycan
LCFA	long-chain fatty acid
MCK-PGC-1 $\alpha$ TG	muscle creatine kinase PGC-1 $\alpha$ transgene/transgenic
mRNA	messenger ribonucleic acid
ND	normal diet
NO	nitric oxide
NRF	nuclear respiratory factor
NRP	neuropilin
PC	parietal cell
PGC-1 $\alpha$	PPAR $\gamma$ coactivator 1 $\alpha$
PIGF	placenta growth factor
PPAR	peroxisome proliferator-activated receptor
qPCR	quantitative polymerase chain reaction
siRNA	short interfering RNA
sVEGFR1	soluble VEGFR1
T2D	type 2 diabetes
<i>Vegfb</i> <sup>-/-</sup>	<i>Vegfb</i> knockout
VEGF(R)	vascular endothelial growth factor (receptor)
WAT	white adipose tissue
WT	wildtype




# 1 INTRODUCTION

During the 3.6 billion years history of life on Earth, several important specialized systems gradually evolved. These evolution processes started about 1 billion years ago, which helped the organisms to leap from single cellular to more complex multicellular structures. The circulatory system in modern higher animals is among these crucial systems. It supports transport of oxygen and nutrients, as well as carbon dioxide and waste metabolites. Vascular endothelial growth factors (VEGFs) and their receptors exert fundamental and crucial roles in the formation, development and maintenance of the circulatory system.

Individual introductions are blended into the chapters below. In Chapter 3 (Paper I), common fatty acid (FA) handling proteins and FA uptake hypotheses are introduced in Section 3.1, followed by an introduction to the endothelial barrier (Section 3.2). In Chapter 4 (Paper II), regulations of VEGFs are introduced in Section 4.1, and the major mitochondrial biogenesis regulator peroxisome proliferator-activated receptor  $\gamma$  coactivator 1 $\alpha$  (PGC-1 $\alpha$ ) is introduced in Section 4.2.1. Randle's cycle and lipid-induced insulin resistance are introduced in Section 4.3.1. In Chapter 5, the roles of VEGFs in tumorigenesis are introduced in Section 5.1.4. Current treatments for insulin resistance and type 2 diabetes (T2D) are introduced in Section 5.2.3. In this chapter, the VEGF family and their receptors are introduced.

## 1.1 VEGFs and their receptors


There are currently five mammalian VEGFs in the family, namely VEGF-A, placenta growth factor (PlGF), -B, -C and -D (Figure 1). There are also two non-mammalian VEGFs, VEGF-E found in orf virus and VEGF-F discovered in snake venom. Three VEGF receptors, together with the co-receptors neuropilins (NRPs) as well as heparan sulfate proteoglycans (HSPGs) and integrins, master downstream VEGF signaling pathways<sup>1,2</sup>.



**Figure 1. Schematic illustration of the domain structures of the five known mammalian VEGFs.** The different domain structures include the VEGF homology domain (in red), the heparin-binding domains at the C-terminal in some splice isoforms of VEGF, PlGF and VEGF-B (in blue), the N-terminal propeptide domains (in yellow), and silk domain-containing C-terminal propeptides in VEGF-C and D (in green). The domains are not drawn in scale. Referenced and modified from Li et al., 2001<sup>3</sup>.

### 1.1.1 VEGF-A signaling through VEGFR2

VEGF-A, also known as VEGF, is the first identified member of the family<sup>4</sup>. Genetic deletion of a single *Vegfa* allele is enough to cause embryonic lethality<sup>5</sup>, indicating its fundamental and crucial functions during embryonic development. VEGF-A is regulated primarily by hypoxia inducible factor 1 $\alpha$  (HIF-1 $\alpha$ ) in response to hypoxia<sup>6,7</sup>. It binds to VEGFR2 and induces phosphorylation of the tyrosine kinase domain. VEGFR2 signaling, induced by the binding of VEGF-A, is responsible for tip cell formation, sprouting, migration, maturation and tube formation of endothelial cells during normal and pathological conditions<sup>1,2</sup> (Figure 2).



**Figure 2. VEGF ligands and their receptors.** Dotted arrows indicate that not all isoforms bind the NRPs. Referenced and modified from Tammela et al., 2005<sup>1</sup>.

### 1.1.2 PIGF

PIGF, encoded by the *PGF* gene, was first isolated from a human placenta cDNA library<sup>8</sup>. PIGF expression is found predominantly in the placenta, heart and lungs<sup>9</sup>. *Pgf* knockout mice did not show any apparent pathological phenotype, indicating that PIGF being dispensable during embryonic development<sup>10</sup>. By studying *Pgf* knockout<sup>10,11</sup> and skin-specific transgenic<sup>11,12</sup> mouse models, PIGF was shown to exert important modifying roles in pathological angiogenesis during ischemia, inflammation, wound healing and cancer.

### 1.1.3 VEGF-B

VEGF-B was the third VEGF family member to be discovered. Being a close homologue, VEGF-B was expected to have similar and redundant functions to VEGF-A and PIGF during angiogenesis<sup>13</sup>. As VEGF-B is the focus of this thesis, it deserves a separate section below (Section 1.2).

#### 1.1.4 VEGFR1 and its ligands

VEGFR1 binds VEGF-A, -B and PlGF with high affinity (Figure 2). Unlike VEGFR2, VEGFR1 shows very low tyrosine phosphorylation activity upon ligand binding<sup>14</sup>, which make its signaling cascade difficult to be captured and studied. When VEGFR1 dimerize with VEGFR2 however, the signaling properties are stronger than homodimers of either receptor<sup>1</sup>. VEGFR1 expression is found primarily in endothelial cells, although it is also seen in other cell types<sup>1</sup>. In Paper I, we found that *Vegfr1* expression was restricted to the cardiac endothelium in mouse heart. Among the three VEGFRs, only VEGFR1 was found to be induced by hypoxia via the HIF-1 $\alpha$  pathway<sup>15</sup>.

The three VEGFR1 ligands are found to exhibit distinct functions in various physiological and pathological processes<sup>1,2</sup>. Binding of either PlGF or VEGF-A to VEGFR1 induces phosphorylation of distinct tyrosine residues and hence regulates different sets of genes<sup>16</sup>. In Paper I, we also showed a unique regulation of downstream target genes by VEGF-B among all three VEGFR1 ligands (Section 3.3.5). VEGF-A was recently shown to be regulated by the PGC-1 $\alpha$ /estrogen-related receptor  $\alpha$  (ERR $\alpha$ ) pathway besides the canonical HIF-1 $\alpha$  pathway<sup>17-20</sup>. In Paper II, we elucidated that VEGF-B can also be regulated by the PGC-1 $\alpha$ /ERR $\alpha$  pathway. The two VEGFR1 ligands, VEGF-A and -B, have distinct expression patterns (Paper I), although both being regulated by PGC-1 $\alpha$ /ERR $\alpha$ . The hypothesis of the regulatory mechanisms behind this differential regulation is discussed in Section 4.2.3.

VEGFR1 binds VEGF-A with higher affinity in comparison to VEGFR2<sup>21</sup> (Figure 2). In angiogenic vasculature, VEGFR2 expression is more profound in the tip cell region whereas VEGFR1 expression is more retained in the stalk cell region<sup>22</sup>. PlGF deficiency impaired VEGF-A signaling<sup>10</sup>. Under certain pathological conditions, PlGF displaces VEGF-A from VEGFR1 and thereby allows higher VEGF-A/VEGFR2 signaling activity<sup>23</sup>. VEGF-A mutants engineered to bind VEGFR1 specifically do not exhibit mitogenic signals in endothelial cells<sup>24</sup>. Furthermore, unlike embryonic lethality of *Vegfr1* deletion due to vessel overgrowth<sup>25,26</sup>, mice lacking the VEGFR1 intracellular kinase domain showed only minor defects in pathological angiogenesis, indicating that VEGFR-1 might function as an inert decoy<sup>10,27</sup>. All these findings point to the “sink” theory that VEGFR1, without exhibiting significant downstream signals, competes the binding of VEGF-A with VEGFR2 and hence modifies its signaling<sup>1,2,28</sup>.

*VEGFR1* encodes a soluble variant through alternative splicing, namely soluble VEGFR1 (sVEGFR1), which contains only the extracellular domains of VEGFR1<sup>29</sup>. Preeclampsia is a pregnancy-specific syndrome of hypertension and proteinuria. Placenta-derived sVEGFR1 has been shown to play an important role during the pathogenesis of preeclampsia<sup>30</sup>. Although these advance, the precise biological role of sVEGFR1 remains to be elucidated.

#### 1.1.5 NRPs and HSPGs

NRP1<sup>31,32</sup> and NRP2<sup>31,33</sup> were isolated from neurons, and were shown to mediate repulsive signals during neuronal axon guidance. Besides class 3 semaphorins<sup>31-33</sup>,

NRP1 binds VEGF-A, -B and PlGF while NRP2 binds VEGF-A, -C and PlGF<sup>34</sup> (Figure 2). NRP1 acts as a co-receptor enhancing VEGFR2 signaling<sup>35</sup>, although NRPs does not seem to show signal transduction properties upon VEGF-A binding<sup>36</sup>. Later studies have shown that the PSD-95/Dlg/ZO-1 (PDZ) binding domain, which consists of three amino acids at the carboxyl-terminal of NRP1<sup>37</sup>, is crucial for its signaling<sup>38</sup>. Genetic deletion of *Nrp1* is embryonic lethal due to vessel malformation, indicating that NRP1 plays roles in embryonic vessel formation, as well as nerve fiber guidance<sup>39</sup>.

HSPGs exist ubiquitously on the cell surface and extracellular matrix. HSPGs bind longer VEGF-A isoforms and facilitate spatial gradient forming, which is crucial for the angiogenesis processes like tip cell formation and sprouting<sup>40</sup>. The shorter VEGF-B isoform, VEGF-B<sub>167</sub>, also binds HSPGs through its hydrophilic carboxyl-terminal<sup>13,41</sup>, but the biological significance of this binding is poorly understood.

#### **1.1.6 VEGF-C, -D and VEGFR3**

Both VEGF-C and -D bind to and signal through VEGFR2 as well as VEGFR3<sup>2</sup> (Figure 2). VEGF-C was shown to be required for sprouting of the first lymphatic vessels from embryonic veins<sup>42</sup>, indicating its pivotal role in lymphangiogenesis. VEGF-C was shown to be responsible for supporting lymphangiogenesis, tumor growth and metastases in various types of cancers<sup>1,2</sup>. Similar to VEGF-C, both in molecular structure and function, VEGF-D can strongly induce angiogenesis and lymphangiogenesis, and also plays a vital role in lymphatic metastasis in a variety types of cancers<sup>2</sup>. VEGFR3 was shown to be important in both angiogenesis and lymphangiogenesis, as genetic deletion of *Vegfr3* in mice was not phenocopied by the double-deletion of *Vegfc* and *Vegfd*<sup>43</sup>.

#### **1.1.7 VEGF-E, and -F**

VEGF-E was found in a parapoxvirus, namely the orf virus. Although VEGF-E isoforms show low amino acid sequence identity, they are structurally highly similar to VEGF-A, and can strongly activate VEGFR2 phosphorylation with high binding affinities<sup>40,44</sup> (Figure 2). VEGF-F is the most recently discovered VEGF member, found in snake venom. Like VEGF-E, it binds specifically to VEGFR2 without heparin-binding properties<sup>45</sup> (Figure 2). Since VEGF-E and -F are the only two VEGFs that bind to VEGFR2 specifically, potential usage in clinical pro-angiogenic therapies was proposed<sup>2</sup>. The existence of the non-mammalian VEGFs is a good example of parallel evolution, which shows the power and beauty of natural selection.

#### **1.1.8 Retrospective of the VEGFs**

VEGF-A was identified already in 1983 as a VPF secreted by tumor cells<sup>4</sup>. In 1989, it was first named as VEGF and its cDNA was cloned<sup>46</sup>. In 1992, VEGF-A was shown to function as a hypoxia-inducible angiogenic factor<sup>6</sup>. Later in 1995, a 28-bp element including HIF-1 consensus sequences in *Vegfa* promoter was identified, which was sufficient to regulate *Vegfa* expression in response to hypoxia<sup>7</sup>. Genetic deletion of *Vegfa* in mice was done in 1996. The study showed that deletion of a single *Vegfa* allele (*Vegfa*<sup>+/-</sup>) was enough to cause embryonic lethality<sup>5</sup>. Coming to the end of the first decade of the 21<sup>st</sup> century, a few recent studies showed that VEGF-A can be

induced by PGC-1 $\alpha$ /ERR $\alpha$  in response to hypoxia and nutrient deprivation, independent of the canonical HIF-1 $\alpha$  pathway<sup>17-20</sup>.


In 1991, PlGF was first isolated and cloned shortly after the identification of VEGF-A<sup>8</sup>. The knockout mouse was generated in 2001 and showed no major abnormality under normal conditions<sup>10</sup>.

VEGF-B was discovered in 1996 as a partial mouse cDNA clone encoding a VEGF-related peptide<sup>13</sup>. Two independent *Vegfb* knockout (*Vegfb*<sup>-/-</sup>) mouse lines were generated respectively in 2000<sup>47</sup> and 2001<sup>48</sup>, which both showed a mild phenotype. The search for the genuine physiological role of VEGF-B lasted more than a decade. In 2005, we found a tight correlation of expression of *Vegfb* with a mitochondrial gene cluster, which is unique in the VEGF family. Subsequently in 2010, an unexpected role of VEGF-B controlling endothelial FA uptake was finally discovered (Paper I). Following this breakthrough finding, the role of VEGF-B in the pathogenesis of insulin resistance and T2D was unveiled this year<sup>49</sup>. This role is further investigated in another high-fat diet (HFD)-induced insulin resistance mouse model in Paper II.

VEGF-C and -D were both discovered in 1996. VEGF-C was purified as a VEGFR3 ligand and had its cDNA cloned from human prostatic carcinoma cells<sup>50</sup>. VEGF-D was isolated from fibroblasts, named as *c-fos*-induced growth factor (FIGF) and was linked to tumor malignancy at the very beginning of its discovery<sup>51</sup>. *Vegfc* knockout mice were generated in the same year and were shown to have severe edema and embryonic lethality<sup>42</sup>. *Vegfd* knockout mice were generated almost a decade later and showed only minor lymphatic phenotypes, indicating it being dispensable during development of the lymphatic system<sup>52</sup>.

VEGF-E and -F were discovered in 1994<sup>44</sup> and 2004<sup>45</sup> respectively. A VEGF-like gene was identified in the genome of orf virus in 1994<sup>44</sup>. In 1998, Ogawa et al. first named the product of this gene as VEGF-E<sup>53</sup>. Since these later VEGFs are not endogenous mammalian VEGFs, only limited number of studies has been done in comparison to other VEGF members.

PlGF was shown to have modifying roles in pathological angiogenesis<sup>10-12</sup>. Number of publications related to PlGF was quickly overtaken by that related to VEGF-C, which is known to exert important roles in lymphatic metastasis<sup>1,2</sup>. VEGF-D has drawn much less attention in comparison to VEGF-C. This is probably due to the fact that VEGF-D is genetically and functionally similar to VEGF-C<sup>1,2</sup>. Nonetheless, the number of publications on VEGF-D still outnumbers that on VEGF-B with a relatively high margin. This is a rough representation to the fact that the gene regulation and role of VEGF-B remained elusive for more than a decade after its discovery (Figure 3).



**Figure 3. Accumulative annual publication numbers on PubMed in the field of VEGF research.** Search criteria: numbers for each VEGF, of which respective abbreviated or full names appearing in the title or abstract in a publication, were counted. The number for VEGF-A is not shown here since it is difficult to distinguish with VEGF or VEGFR in general.

## 1.2 VEGF-B

VEGF-B binds to VEGFR1 and NRP1<sup>54</sup>, and has two mRNA splicing variants<sup>41</sup>. The shorter form VEGF-B<sub>167</sub> binds to the extracellular matrix and is the predominant isoform under normal physiological conditions<sup>13</sup>. The longer form VEGF-B<sub>186</sub>, on the other hand, is freely diffusible and was found to be upregulated in various forms of tumors<sup>55</sup>. In Paper I, VEGF-B<sub>186</sub> was shown to induce higher fatty acid transporter protein (FATP) expression and FA uptake than VEGF-B<sub>167</sub> *in vitro*. Abundant VEGF-B expression was found in metabolic active tissues such as heart, skeletal muscle and brown fat<sup>48</sup>. *Vegfb*<sup>-/-</sup> mice were generated with the hope to reveal its function. In contrast to *Vegfa*, genetic deletion of *Vegfb* in mice resulted in a mild phenotype<sup>47,48</sup>.

In the following years, the mystery of VEGF-B was unveiled piece by piece after another. Unlike VEGF-A, VEGF-B is poorly angiogenic and not regulated by hypoxia<sup>23,56,57</sup>. In a rabbit hindlimb ischemia model however, VEGF-B gene transfer was shown to be beneficial<sup>58</sup>. VEGF-B was also shown to stimulate neurogenesis<sup>59</sup> and have neuroprotective effects<sup>60-62</sup>. A more recent study showed that VEGF-B inhibits apoptosis by suppression of BH3-only protein gene expression via VEGFR1 signaling<sup>63</sup>. Heart-specific VEGF-B overexpression in mice was shown to alter cardiac ceramide accumulation and it induces myocardial hypertrophy<sup>64</sup>. Although the advances, the whole picture of VEGF-B biology was still like a huge jigsaw puzzle with only a few pieces put in place. Even after the functions of the more recently identified VEGFs were well established, the role and gene regulation of VEGF-B remained enigmatic and controversial.

In Paper I, a number of published microarray data sets were pooled and analysed. The original aim of the analysis was to identify sets of co-expressed genes, including new mitochondrial genes. However, VEGF-B, a VEGF member was never thought to be

correlated with mitochondrial functional, and it surfaced with an astonishing high correlation coefficient ( $r = 0.90$ ). In comparison, other VEGF family members showed much lower or even no correlation at all (VEGF-A,  $r = 0.30$ ; PlGF,  $r = -0.18$ ; and VEGF-C,  $r = -0.10$ ). Early VEGF-B studies have already showed this once overlooked this correlation as high expression of VEGF-B was found in tissues with high mitochondrial content, such as heart, skeletal muscle, brown fat and kidney. This was the starting point for the discovery of the function of VEGF-B. Following these initial findings, the thesis work has answered two fundamental questions that remained unclear in VEGF-B research: the physiological role (Paper I) and gene regulation (Paper II) of VEGF-B.

## 2 AIMS


The correlation of *Vegfb* expression with mitochondrial gene expression was unexpected. Based on this finding, we have established the following aims:

To characterize the role of VEGF-B in tissue FA uptake and its signaling pathways (**Paper I**);

To phenotype *Vegfb*<sup>-/-</sup> mice in identifying the physiological consequences of genetic deletion of *Vegfb* (**Paper I**);

To identify the molecular regulatory mechanism of *Vegfb* (**Paper II**).

After identifying PGC-1 $\alpha$  as a major regulator of *Vegfb*, we set yet another aim:  
To characterize the physiological consequences of genetic deletion of *Vegfb* in a PGC-1 $\alpha$  transgenic mouse model (**Paper II**).



**Figure 4. Schematic illustration of the working hypothesis on gene regulation and role of VEGF-B.** VEGF-B is secreted in parallel with mitochondrial biogenesis upon activation of ERR $\alpha$  coactivated by PGC-1 $\alpha$ . VEGF-B then instructs the endothelium to upregulate FATPs for an increase of FA influx from the blood stream via VEGFR1 and NRP1 signaling. As a consequence, the increase in FA uptake matches elevated  $\beta$ -oxidation capacity in the mitochondria to fulfill the higher energy demand in the tissue cell.



### 3 PAPER I: VEGF-B CONTROLS ENDOTHELIAL FA UPTAKE

#### 3.1 Current view and hypotheses of FA transport

Due to the bipolar nature of FA molecules, it was believed that FA transport across mammalian cell membranes is a combination of passive flip-flop and protein-mediated diffusion<sup>65,66</sup>. Several membrane proteins associated with long-chain fatty acid (LCFA) uptake have been identified including FATPs and CD36<sup>65</sup>.

Due to the intrinsic very long-chain acyl-CoA synthetase (VLACS) activity, it was debated whether FATPs are also solute carriers<sup>67</sup>. Among the six FATPs identified, FATP1 and 6 express in the heart, while FATP1, 3 and 4 express in the skeletal muscle<sup>65</sup>. In Paper I, we have shown that *Fatp3* expression is restricted in the cardiac and muscular endothelium.

The transmembrane glycoprotein CD36 has been identified as a putative transporter of LCFAs<sup>68</sup>. Subsequent *in vitro* and *in vivo* studies have provided strong support for a role of CD36 in FA transport<sup>69</sup>. Studies on various transgenic and genetic deletion mouse models of *Cd36* have confirmed the hypothesis that it facilitates a major fraction of FA uptake in heart, skeletal muscle, and adipose tissues, where it is highly expressed<sup>69</sup>.

Tight endothelial cell layer exists between the blood and the tissue cells in most of the organs. Despite of this fact, the dominant consensus in the field of FA transport is that the rate-limiting step of FA uptake occurs at the plasma membrane of the tissue cells, with large ignorance of the endothelium.

#### 3.2 Post-angiogenesis: the endothelial barrier

The process of vessel sprouting was documented as early as in the 17<sup>th</sup> century<sup>70</sup>. In the late 1960s, a diffusible angiogenic factor derived from tumors was identified and the term “tumor angiogenesis” was first coined<sup>71</sup>. Blood vessels, which are composed of endothelial cells and mural cells, support normal and tumor tissue with oxygen and nutrient. This simple fact has led the field of vascular biology research focused on studying the pure extension of the endothelium without considering phenotypical changes at early years. In the early 1970s, Folkman proposed targeting angiogenesis as a treatment for malignant tumors<sup>72</sup>. Later studies on anti-angiogenesis therapies have brought more attentions to vessel maturation after the initial growth, including changes in endothelial cell junctions, pericyte coverage as well as functional changes such as blood perfusion<sup>70,73</sup>.

Except for the smallest molecules like oxygen, carbon dioxide and nitric oxide (NO), the transport of most of molecules across the cell membranes are tightly controlled processes. Even water molecules were found to be transported in a controlled manner in certain tissues<sup>74</sup>. With the notion of the endothelial barrier in mind, we hypothesized that the transport of FA across the endothelial cell layer in most tissues is also a tightly controlled mechanism.

### 3.3 Physiological role of VEGF-B

#### 3.3.1 The starting point and the working hypothesis

Two independent bioinformatic analyses of published data had pointed to the same conclusion: VEGF-B, but not any other VEGFs, is highly correlated with mitochondrial genes. Two additional qPCR analyses have also shown similar gene expression patterns of *Vegfb* with two mitochondrial markers, *Ndufa5* (encodes NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 5) and *Cytc* (encodes cytochrome c, somatic), across a variety of mouse tissues and nutritional states. Genetic deletion of *Vegfb* has no influence on mitochondria copy number in mouse heart. These findings indicate that VEGF-B is closely related to mitochondrial function and there is no direct feedback loop between *Vegfb* and mitochondrial gene expression.

We then hypothesized that in the most energy demanding tissue cells, while mitochondrial biogenesis is underway, VEGF-B is secreted in parallel to instruct the endothelium for more FA transport from the blood stream. In this way, increased FA uptake matches up with higher mitochondrial content in the tissue cells for elevated energy production.

#### 3.3.2 VEGF-B controls endothelial FA uptake *in vitro*

We first tested if VEGF-B regulates FA handling genes in endothelial cells *in vitro*. Both VEGF-B isoforms increased mRNA and protein levels of several FATPs across a number of endothelial cell lines. Pre-incubation of respective neutralizing antibodies with the endothelial cells prior to addition of VEGF-B unveiled that this effect is dependent on VEGFR1 and NRP1, but not VEGFR2. In contrast, neither VEGF-A nor PlGF, the other VEGFR1 ligands, can upregulate these FATPs. Furthermore, applying VEGF-B to a fibroblast cell line (NIH/3T3) did not induce FATP expression, indicating endothelial-cell-specific signaling pathway and/or transcription machinery being involved. A kinase inhibitor screening unveiled that the induction of FATP expression by VEGF-B is dependent on phosphatidylinositol-3-OH kinase (PI3K) pathways.

Since the exact mechanism of cellular FA uptake by FATPs is debated<sup>65,67</sup>, we examined whether VEGF-B can induce LCFA accumulation through FATPs in cells, with a fluorophore-labeled LCFA analogue as the marker. By overexpressing (transient transfection) or silencing (using siRNA) *Fatp3/4* in endothelial cells, with or without addition of VEGF-B, we have shown that this LCFA uptake is VEGF-B-dependent via the FATPs. Interestingly, similar experiments done on HL-1 cells, a cardiomyocyte cell line, did not alter LCFA uptake. This gives more evidence that the induction of FA uptake by VEGF-B via FATPs is endothelial-cell-specific.

To closer mimic *in vivo* FA transport across the endothelium, we utilized cell culture inserts. Cultured endothelial cells can form a tight monolayer which creates two isolated liquid compartments. VEGF-B treatment increased <sup>14</sup>C-OA transport across the endothelial cell layer in a NRP1-dependent manner, indicating VEGF-B controls trans-endothelial LCFA transport.

### 3.3.3 VEGF-B controls endothelial FA uptake *in vivo*

To determine whether VEGF-B signaling is endocrine or paracrine manner, we isolated endothelial cells from mouse heart. In *Vegfb*<sup>-/-</sup> heart, only endothelial expression of *Fatp3* and *Fatp4* was decreased, indicating that VEGF-B signals in a paracrine fashion. Adenoviral administration of VEGF-B in mouse heart increases *Fatp* expression whereas genetic deletion of *Vegfb* in mice decreased it. Intracellular lipid accumulation was reduced in *Vegfb*<sup>-/-</sup> heart, soleus and brown adipose tissue (BAT) compared to the wildtype (WT) counterparts. A similar decrease of *Fatp* expression and lipid accumulation was also found in tamoxifen-treated EC-SCL-Cre-ER<sup>T</sup>-positive *Nrp1*<sup>fl/fl</sup> (endothelial-cell-specific *Nrp1* knockout, *Nrp1-EC*<sup>-/-</sup>) mice. Overexpressing VEGF-B by systemic adenoviral infection in *Vegfb*<sup>-/-</sup> mice rescued *Fatp* expression and lipid accumulation, in but not *Nrp1-EC*<sup>-/-</sup> mice. These results indicate that VEGF-B regulates endothelial FA uptake *in vivo* in a NRP1-dependent manner.

### 3.3.4 Phenotyping of the *Vegfb*<sup>-/-</sup> mice

*Vegfb*<sup>-/-</sup> mice showed less lipid accumulation in energy demanding tissues and were 15% heavier compared to WT littermates at 16 to 18 weeks of age. We then tested kinetics of tissue FA uptake with oral gavage of radio-labeled LCFA. Two hours after the gavage, less <sup>14</sup>C-OA accumulation was seen in *Vegfb*<sup>-/-</sup> heart, soleus and BAT comparing to the WT counterparts while the accumulation in white adipose tissue (WAT) remained the same. However, after 24 hours, <sup>14</sup>C-OA accumulation in *Vegfb*<sup>-/-</sup> WAT increased drastically and was significantly higher than in the WT. Magnetic resonance imaging (MRI) analysis also showed a higher body fat percentage in *Vegfb*<sup>-/-</sup> mice compared to WT. These findings indicate that excess fat in *Vegfb*<sup>-/-</sup> mice is shunted to WAT for storage.

Back in 1963, Randle et al. have proposed a mechanism that glucose and FA competes for substrates in metabolic processes, named the Randle's cycle<sup>75,76</sup>. Randle's cycle is one of the most important metabolic processes during the development of insulin resistance and T2D<sup>75-78</sup>. The involvement of Randle's cycle in lipotoxicity-induced muscular insulin resistance will be discussed in more details below (Section 4.3.1).

In a micro positron emission tomography (micro-PET) scan analysis, *Vegfb*<sup>-/-</sup> mice accumulated significantly more [<sup>18</sup>F]FDG, a glucose homologue, within 60 min in heart compared to WT mice. This finding indicate that genetic deletion of *Vegfb* results in the reduction of FA uptake in tissues, and in turn induces a metabolic shift towards more glucose usage. Except for the VEGF-B-mediated pathway, there are more regulatory pathways controlling FA uptake in various tissues, which will be discussed in Paper II. Despite of these facts, inactivation of a single gene *Vegfb* alone, is enough to alter whole-body fat distribution and tissue preferences for energy molecules. These findings hinted that VEGF-B also plays a role in insulin resistance induced by muscular lipid accumulation and pathogenesis of T2D. We have further tested this hypothesis in one of our recent studies<sup>49</sup> as well as in Paper II.

### 3.3.5 Unique downstream effects of VEGF-B via VEGFR1

Among all the VEGFR1 ligands tested, only VEGF-B upregulated *Fatps* in endothelial cells *in vitro* and *in vivo*. Ten times molar excess of PlGF did not even attenuate this effect *in vitro*. Furthermore, adenoviral administration of PlGF into mouse heart did influence *Fatp* expression. These results indicate differential receptor binding sites and/or structural variants. Recruitment of unidentified unique co-receptors is another intriguing hypothesis. These findings are in line with the notion that the three VEGFR1 ligands activate distinct signaling pathways and induce different downstream effects.

## 3.4 Conclusion

In conclusion, we elucidated a VEGFR1- and NRP1-dependent FA uptake in endothelial cells controlled by VEGF-B via FATPs. This regulation of FA uptake is unique to VEGF-B in contrast to VEGF-A and PlGF. *Vegfb*<sup>-/-</sup> mice had less FA uptake in the most energy-demanding tissues but shunted the excess FA to WAT. *Vegfb*<sup>-/-</sup> mice had a metabolic shift towards more glucose usage in the heart compared to WT mice. Our study here has established a direct link for two research fields, angiogenesis and metabolism.

## 4 PAPER II: *Vegfb* IS REGULATED BY PGC-1 $\alpha$

### 4.1 Gene regulation of VEGFs


VEGF-A is known to be regulated by the traditional “hypoxia - HIF-1 $\alpha$ ” pathway<sup>6,7</sup> as well as the recently found “hypoxia/nutrient deprivation - PGC-1 $\alpha$ /ERR $\alpha$ ” pathway<sup>17-20</sup>. VEGF-A can also be induced by a number of cytokines including interleukins (ILs), insulin-like growth factor 1, basic fibroblast growth factor, epidermal growth factor and transforming growth factors (TGFs)<sup>79</sup>. PlGF is readily upregulated in pathological conditions by stimuli such as hypoxia, NO, inflammatory cytokines (IL-1 and tumor necrosis factor  $\alpha$ , TNF $\alpha$ ), oncogenes (*HRAS*) and growth factors (VEGF-A and TGF $\beta$ )<sup>80</sup>. Pro-inflammatory cytokines were shown to regulate *Vegfc* expression<sup>81</sup>. Putative nuclear factor-kappa B (NF- $\kappa$ B) binding sites were further identified in *Vegfc* promoter<sup>82</sup>. This finding indicates that the induction of *Vegfc* by TNF $\alpha$  and IL-1 may be NF- $\kappa$ B-mediated<sup>2</sup>. VEGF-D expression has been shown to correlate with lymphatic metastasis across a variety of tumors<sup>1,2</sup>, but its gene regulatory mechanism is still poorly understood.

Although quite a few studies have explored *Vegfb* expression in different contexts, its molecular regulatory mechanism remained enigmatic. Not long after its discovery, it has already been shown that, unlike VEGF-A, VEGF-B is not regulated by hypoxia<sup>57</sup>. Early tissue expression studies have hinted a correlation of VEGF-B with metabolism<sup>48</sup>. Several studies have implied this correlation: a microarray study in the aim of identifying potential peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) target genes has shown an upregulation of *Vegfb* by rosiglitazone, a PPAR $\gamma$  agonist in mouse aorta<sup>83</sup>; another microarray study showed that *Vegfb* was downregulated by experimental type 1 diabetes and attenuated by long-term endurance training<sup>84</sup>; a more recent study showed that muscle-specific loss of nuclear receptor corepressor 1 in mice could induce mitochondrial function in parallel with *Vegfb* expression<sup>85</sup>; two independent muscle-specific PGC-1 $\alpha$  transgenic mouse lines have been shown to have elevated *Vegfb* expression levels in the muscle<sup>86,87</sup>. Furthermore, in Paper I, we identified a tight correlation of *Vegfb* with a large cluster of mitochondrial genes. All these findings point to a regulation of VEGF-B in parallel with mitochondrial biogenesis.

### 4.2 PGC-1 $\alpha$ regulates *Vegfb* and mitochondrial biogenesis

#### 4.2.1 PGC-1 $\alpha$ and mitochondrial biogenesis

PGC-1 $\alpha$ , a major regulator in mitochondrial biogenesis, coactivates a number of transcription factors including PPARs, ERR $\alpha$  and nuclear respiratory factors (NRFs). ERR $\alpha$  is a ligand-independent orphan nuclear receptor which exerts vital roles in various physiological conditions such as exercise and cold adaptation. The PGC-1 $\alpha$ /ERR $\alpha$  transcription complex is a known regulator of mitochondrial biogenesis<sup>88-98</sup> and in Paper I, *Vegfb* expression was found to be tightly correlated with mitochondrial genes. We then tested the hypothesis that *Vegfb* is co-regulated with mitochondrial genes by ERR $\alpha$  when coactivated by PGC-1 $\alpha$  (Figure 5).



**Figure 5. PGC-1 $\alpha$  and mitochondrial biogenesis.** Physiological stimuli such as cold, fasting and exercise drive the expression of PGC-1 $\alpha$ , which then upregulates a set of downstream genes through coactivation of a number of transcription factors including PPARs, ERR $\alpha$  and NRFs. There are positive feedback loops for the expression of PGC-1 $\alpha$  and some of the transcription factors. Subsequently, mitochondrial biogenesis is initiated. We wanted to test if VEGF-B is regulated in parallel. NRs, nuclear receptors; UCP, uncoupling protein; COX, cytochrome c oxidase; mtTFA, mitochondrial transcription factor A.

#### 4.2.2 PGC-1 $\alpha$ regulates *Vegfb* through coactivation of ERR $\alpha$ *in vitro*

NO is known to trigger PGC-1 $\alpha$ -mediated mitochondrial biogenesis in cells, which was dependent on cyclic guanosine monophosphate (cGMP)<sup>99</sup>. By applying an NO donor on C2C12 myotubes, we were able to activate this pathway and induce *Vegfb* as well as mitochondrial genes. The expression of *Vegfa* and *Pgf*, however, remained unchanged after the treatment. This differential expression pattern of *Vegfb* vs. *Vegfa/Pgf* is in line with our previous findings in Paper I. But at first look, PGC-1 $\alpha$  failed to regulate *Vegfa* expression, which is seemingly contradictory to a previous finding<sup>17</sup>. We focused on chronic effect of NO (days) like Nisoli et al. tested<sup>99</sup>, while Arany et al. tested *Vegfa* expression by PGC-1 $\alpha$  upregulation in a short-term setup (hours)<sup>17</sup>. Whether *Vegfa* is upregulated within hours of NO stimulation in the myotubes or not, remains to be tested.

In a time course study, we saw an initial downregulation of *Vegfa* in C2C12 myotubes and the expression returned to basal level after 16 hours of serum deprivation. Again, this finding seemingly does not come in line with what Arany et al. have found<sup>17</sup>. This can be explained by: 1) different choice of cell lines: we chose C2C12 myotubes, since its *in vivo* counterpart is a primary source of VEGF-B expression, while Arany et al. chose 10T $\frac{1}{2}$  as a natural VEGF-A expressing cell line. 2) other experimental conditions: serum deprivation alone in comparison to that in combination with hypoxia. Hypoxia does not regulate VEGF-B expression and hence is not the focus of this paper.


ERR $\alpha$  recognizes the consensus DNA sequence AGGTCA<sup>100</sup>. Mutation of the putative ERR $\alpha$  binding site "AGGTCC" at 566 base pair upstream of *Vegfb* greatly attenuated, instead of abolishing, the induction of luciferase activity in the reporter assay. ERR $\alpha$

itself has been shown to bind to specificity protein 1 (Sp1) and to activate thyroid hormone receptor  $\alpha$  (TR $\alpha$ ) through an Sp1 binding site<sup>101</sup>; moreover, ERR $\alpha$  has recently been shown to induce the expression of Sp1<sup>102</sup>. ERR $\alpha$  has also been shown to activate PPAR $\alpha$  gene expression via direct binding to the PPAR $\alpha$  promoter<sup>103</sup>. PPAR $\alpha$  binds to the same response element as PPAR $\gamma$ <sup>92</sup>. In this paper, we also show that PPAR $\gamma$ , without additional ligands other than the free FA and lipid metabolites presented in the serum, modestly induced the *Vegfb* promoter in the luciferase assay. Taken these findings together, it can at least partially explain the remaining promoter activity with the absence of the functional ERR $\alpha$  binding sites in respective *Vegfb* promoter and intron constructs. Chromatin immunoprecipitation (ChIP) assay could confirm whether PGC-1 $\alpha$ /ERR $\alpha$  transcription complex binds to the putative ERR $\alpha$  response element.

#### 4.2.3 Differential regulation of *Vegfb* and *Vegfa*

VEGF-A-mediated angiogenesis is vital for tissue remodeling in response to exercise training<sup>104,105</sup> and cold adaptation<sup>19</sup>. In response to these physiological stimuli, PGC-1 $\alpha$  regulates mitochondrial genes, *Vegfb* as well as *Vegfa*<sup>17,18,20</sup> through co-activation of ERR $\alpha$ . These findings point to a co-regulation of VEGF-A and VEGF-B in parallel with mitochondrial biogenesis. This suggestion is, however, contradictory from what we found in Paper I, where *Vegfb* has a tight correlation with mitochondrial gene cluster but not *Vegfa*.

After a single bout of intensive exercise, *Vegfa* mRNA needs to be downregulated to basal level after the initial peak to avoid exceeded angiogenic response<sup>106</sup>. VEGF-B, on the other hand, modulates physiological function other than growth of the endothelium, which may partially explain why modest *Vegfb* upregulation can only be observed after long-term endurance training<sup>84</sup>. Furthermore, mitochondrial biogenesis is a nutrient- and energy-demanding and hence time-consuming biological process, with which VEGF-B expression should be synchronized. We believe this differential regulation of VEGF-B and VEGF-A is crucial for tissue remodeling in response to various physiological stimuli. It is known that VEGF-B is not regulated by hypoxia<sup>57</sup>. One hypothesis is that under hypoxic conditions, certain transcription factors, other than ERR $\alpha$ , regulate *Vegfa* expression when coactivated by PGC-1 $\alpha$ . Variation in *Erra* expression pattern in response to hypoxia and/or nutrient deprivation could also play a key role in the putative differential regulation of the two VEGFs (Figure 6).



**Figure 6. A schematic illustration of the differential regulation of VEGF-B and VEGF-A in the context of tissue remodeling.** The unknown components underlying the differential regulation of the VEGFs by hypoxia are marked in red. The gray dotted line indicates a possible link between VEGF-B expression and muscle fibre type switching described in Paper II. Referenced and modified from Arany et al. 2010<sup>17</sup>. MEF2, myocyte enhancer-binding factor 2.

### 4.3 VEGF-B mediates insulin resistance in MCK-PGC-1α TG mice

#### 4.3.1 Randle's cycle, muscular lipid accumulation and insulin resistance

Substrate competition for respiration in animal tissues has been known for almost a century<sup>76</sup>. In 1963, Randle proposed a “Glucose Fatty Acid Cycle” theory, also known as the Randle cycle, which is a metabolic process involving substrate competition of glucose and FA in respiratory oxidation<sup>75</sup>. FA oxidation inhibits glucose catabolism and stimulates gluconeogenesis and glucose storage, while glucose oxidation inhibits FA oxidation and promotes storage for both fuel substrates<sup>76</sup>. In the original publication, Randle already hypothesized an important role of the cycle in the pathogenesis of insulin resistance and T2D, even though the inferred underlying molecular mechanism was later proven wrong<sup>75</sup>.

Lipid accumulation in skeletal muscle and liver may be a result of increased uptake and/or synthesis of FA when total energy intake exceeds the storage capacity of the adipose tissue. Acquired or inherited mitochondrial dysfunction may also lead to muscular lipid accumulation<sup>77</sup>. This pathological accumulation will in turn promote development of insulin resistance and T2D.



The molecular mechanisms underlying the lipid-induced insulin resistance has been studied intensively for the past two decades although still not fully understood. Early observations revealed a negative correlation of insulin resistance with plasma FA concentrations and intramyocellular lipid content<sup>107</sup>. Lipid infusion studies pointed to the theory that defects in glucose transport, but not impaired glycolysis as hypothesized by Randle, was underlying the insulin resistance induced by high plasma FA concentrations<sup>107</sup>. Glucose transporter 4 (GLUT4) is highly expressed in adipose tissue and skeletal muscle<sup>108</sup>. It is acutely translocated to the cell membrane upon stimulation of insulin signaling and increase cellular glucose uptake. This translocation was found to be compromised in T2D patients<sup>109</sup>.

Later studies indicated a role of diacylglycerol, a metabolite from triglyceride, in lipid-induced insulin resistance. In both mice and human subjects, it was shown that insulin resistance was associated with high intramyocellular diacylglycerol but not triglyceride accumulation<sup>107</sup>. Now the common consensus is that diacylglycerol-induced malfunction in insulin signaling and hence insulin resistance is via activation of novel protein kinase C (PKC) serine-threonine kinases<sup>107</sup>. Inflammatory signals in WAT<sup>110</sup> and impaired GLUT4 translocation induced by muscular lipid droplet accumulation<sup>111</sup> have also been linked with lipid-induced insulin resistance.

#### 4.3.2 The paradox of PGC-1 $\alpha$ overexpression and insulin resistance


Choi et al. have identified a paradoxical effect of increased expression of PGC-1 $\alpha$  on muscle mitochondrial function and insulin-stimulated muscle glucose metabolism<sup>112</sup>. They originally hypothesized that muscular PGC-1 $\alpha$  overexpression would prevent against HFD-induced insulin resistance in mice, since two microarray studies have implicated decreased PGC-1 $\alpha$  expression in T2D patient samples<sup>112</sup>. But paradoxically, they found decreased insulin sensitivity in the muscle creatine kinase PGC-1 $\alpha$  transgenic (MCK-PGC-1 $\alpha$  TG) mice compared to WT mice when fed a HFD.

In Paper I, we showed an increased cardiac glucose uptake capacity in *Vegfb*<sup>-/-</sup> mice. This was the first indication that VEGF-B deficiency could be beneficial in insulin resistance. Our recent study has further shown that VEGF-B inactivation in various diabetes animal models reduced lipid accumulation in muscle and halted the development of T2D<sup>49</sup>. Based on these findings, we hypothesized that in HFD-fed MCK-PGC-1 $\alpha$  TG mice, lipid accumulation exceeds mitochondrial  $\beta$ -oxidation capacity due to VEGF-B hyperactivity, and hence promotes insulin resistance. We were then interested to test *Vegfb* inactivation in the context of HFD-induced insulin resistance in MCK-PGC-1 $\alpha$  TG mice.

#### 4.3.3 *Vegfb*: the missing link which solves the paradox

We crossed *Vegfb*<sup>-/-</sup> with MCK-PGC-1 $\alpha$  TG mice to create the MCK-PGC-1 $\alpha$  TG // *Vegfb*<sup>-/-</sup> strain. After 15 weeks on a HFD, insulin resistance and glucose intolerance were ameliorated in these mice. The levels of plasma glucose, insulin and triglyceride were also normalized, or nearly-normalized, to lean WT levels. These phenotypes could be attributed by decreased lipid accumulation in the MCK-PGC-1 $\alpha$  TG // *Vegfb*<sup>-/-</sup> muscle compared to the MCK-PGC-1 $\alpha$  TG counterpart.

At the time Choi's study was published, the "PGC-1 $\alpha$ /ERR $\alpha$  — VEGF-B — fatty acid uptake" regulatory axis has not been revealed. If taken this regulatory axis into account, the findings by Choi et al. are not paradoxical anymore: under a normal diet, not only mitochondrial biogenesis is upregulated by the PGC-1 $\alpha$  overexpression in the muscle but VEGFB-mediated FA uptake is upregulated in parallel; when the two arms, mitochondria and FA uptake, are both induced, the balance of  $\beta$ -oxidation will still be even (Figure 7). When MCK-PGC-1 $\alpha$  TG mice are fed a HFD, similarly as in WT mice, insulin sensitivity will decrease due to lipid accumulation in the muscle exceeding the  $\beta$ -oxidation capacity in the mitochondria. But when VEGF-B is absence in the muscle, even under a double challenge of HFD and PGC-1 $\alpha$  overexpression, FA uptake still matches the capacity of mitochondrial  $\beta$ -oxidation. This balance will in turn attributes to the ameliorated insulin sensitivity.



**Figure 7. PGC-1 $\alpha$  balances the two arms of  $\beta$ -oxidation** (same as Figure 6a in Paper II).

#### 4.4 Conclusion

In conclusion, we elucidated a new "PGC-1 $\alpha$ /ERR $\alpha$  — VEGF-B — fatty acid uptake" regulatory axis. Adding VEGF-B in the knowledge of the complex metabolic regulatory network leads to a better understanding of the balance of  $\beta$ -oxidation and lipid homeostasis in the body. Genetic deletion of *Vegfb* in MCK-PGC-1 $\alpha$  TG mice reduced muscular lipid accumulation but did not influence postprandial blood glucose or glucose tolerance under normal diet (ND). Under a HFD however, deletion of *Vegfb* under the muscle-specific PGC-1 $\alpha$  transgene normalized postprandial blood glucose, drastically reduced plasma triglyceride and insulin, as well as restored glucose tolerance and insulin sensitivity. These improved metabolic characteristics are likely attributed to reduced muscular lipid accumulation. Our findings provided new evidence showing the vital role of VEGF-B in HFD-induced insulin resistance and pathogenesis of T2D. Targeting VEGF-B as a therapeutic approach in treating insulin resistance and development of T2D has promising clinical implications.

## 5 FUTURE PERSPECTIVES

### 5.1 Role of VEGF-B in other contexts

Mitochondrial biogenesis is induced upon various physiological stimuli, such as in skeletal muscle after exercise and in brown adipose tissue after cold exposure<sup>93</sup>. It is then logical to explore the role of VEGF-B upon these stimuli. The cell type that has the highest mitochondrial content in mammals is the acid-secreting parietal cell (PC) in the stomach mucosa<sup>113</sup>. Since VEGF-B is also highly expressed in PC, we have investigated whether it has a role in this type of cells. The role of VEGF-B in tumorigenesis is also discussed here.

#### 5.1.1 Role of VEGF-B in endurance running

Exercise training is known to induce mitochondrial biogenesis<sup>93</sup>. We hypothesized that *Vegfb* is upregulated after long-term endurance training together with mitochondrial genes and *Vegfb*<sup>-/-</sup> mice have reduced running capacity. After training for 28 days (10 m/min, 48 min per day), we could not detect any difference in running capacity between WT and *Vegfb*<sup>-/-</sup> mice (unpublished data). In quadriceps, when comparing trained WT mice to sedated littermates, *Vegfb* was downregulated together with *Hadh*, the gene coding for a key  $\beta$ -oxidation enzyme, hydroxyacyl-coenzyme A dehydrogenase (unpublished data). This result indicates that the running speed was insufficient to induce an endurance training stimulus, since the muscle is known to primarily utilize glucose in long-term low-intensity running or high-intensity sprint<sup>76</sup>. *Vegfb* was found to be upregulated following a long-term endurance running protocol in mice<sup>84</sup>. Therefore, optimizations of our current running protocol are needed for further testing of our hypothesis.

#### 5.1.2 Role of VEGF-B in cold adaptation

Mitochondrial biogenesis plays a key role in brown fat activation during cold adaptation in mice<sup>93</sup>. To test the role of *Vegfb* in cold adaptation, we subjected mice to 4°C for 28 days. We found no difference in body temperature adaptation between WT and *Vegfb*<sup>-/-</sup> mice, but surprisingly, there was a delayed body weight increase in the *Vegfb*<sup>-/-</sup> mice compared to WT littermates (unpublished data). This finding indicates that *Vegfb*-mediated FA uptake in the brown adipocytes could be a rate-limiting step for brown fat development upon cold stimulation. Further analyses of the tissue need to be performed for testing this hypothesis.

#### 5.1.3 The most “energetic” cell type in the body

The acid-producing PC in the stomach mucosa is one of the cell types with the highest level of energy consumption. This type of cells are filled with mitochondria and can develop a proton gradient of more than one million-fold across the membrane of the secretory canaliculus. Similarly to brown adipocytes, cardiac- and skeletal myocytes, which all have high level of VEGF-B expression and mitochondrial content, PCs also mainly use fatty acids as energy source<sup>113</sup>.

A study has found that *Vegfb* was among a number of genes that were not previously reported to be expressed in PC<sup>113</sup>. *Vegfb* has even been identified as a PC-specific marker<sup>114</sup>. Upon *Helicobacter pylori* (*Hp*) infection, *Vegfb* expression was highly upregulated<sup>113</sup>. These findings indicate potential roles of *Vegfb* in gastric-acid secretion and pathogenesis of stomach ulcer and gastric cancer, which are known to be closely linked with *Hp* infection<sup>115,116</sup>.

The apical membrane of the parietal cell contains an  $H^+/K^+$ -ATPase, which is the primary  $H^+$  pump and also a marker for PC<sup>114</sup>. Our unpublished data have both shown that VEGF-B and  $H^+/K^+$ -ATPase are co-localized and restrictedly expressed in PCs in the stomach mucosa. Another study also confirmed this co-localization<sup>114</sup>. We could not detect any difference in the vascular networks between WT and *Vegfb*<sup>-/-</sup> gastric mucosae. Based on this observation, we then hypothesized that in the gastric mucosa, *Vegfb* is highly expressed in PC to coordinate FA uptake and mitochondrial  $\beta$ -oxidation, rather than regulating or maintaining the vasculature. Further examinations of gastric-acid secretion and experimental gastric ulcer induction in *Vegfb*<sup>-/-</sup> mice will help us to have more insights to the potential role of VEGF-B in gastric mucosa.

#### 5.1.4 Role of VEGF-B in tumorigenesis

Angiogenesis is a crucial step during tumor progression. The roles of the VEGFs in tumorigenesis were studied rather intensively throughout the years<sup>2</sup>. VEGF-A, was first identified as a growth factor secreted by tumor cells<sup>4</sup>. It is upregulated in many, if not all, human solid tumors<sup>14</sup>. These findings marked the starting point of the following intensive research on anti-VEGF-A treatments of solid tumors<sup>117</sup>. It was shown that PlGF expression correlates with disease progression and patient survival and may be used as a prognostic indicator for colorectal cancer<sup>118</sup>. Implication of PlGF being a therapeutic target in Ewing's sarcoma was proposed<sup>119</sup>. Anti-PlGF treatment of various kinds of tumors was proposed followed by some controversial results<sup>120-123</sup>. Since sVEGFR1 can sequester VEGF-A, -B and PlGF, sVEGFR1-based traps have been developed, along with VEGFR1 inhibitors and antibodies, as anti-angiogenesis agents<sup>80</sup>. Gene transfer of sVEGFR1 has recently been proposed as a new anti-angiogenic cancer therapy<sup>124</sup>. Both VEGF-C and -D were linked to tumor malignancy and lymphatic metastasis in cancers since the beginning of their discovery<sup>1,2</sup>.

The freely-diffusible longer VEGF-B isoform, VEGF-B<sub>186</sub>, was shown to be upregulated in mouse and human tumor cell lines and primary tumors<sup>55</sup>. But in contrast to other VEGFs, very few studies have explored the role of VEGF-B in the context of tumorigenesis. Among them, one study by Albrecht et al. is noteworthy. They have investigated the function of VEGF-B in tumorigenesis by the generation of two mouse models of pancreatic cancer. Beta-cell-specific overexpression of VEGF-B in the pancreatic islet carcinoma mouse model retarded tumor growth. Conversely, the same mouse model deficient for *Vegfb* presented with larger tumors. These results led to the questioning of indiscriminate blocking of VEGF signaling in anti-angiogenesis therapies<sup>125</sup>.


In order to investigate the functional role of the VEGF-B during tumorigenesis, we generated tumor cells that overexpress either the soluble or the heparin-binding isoform of VEGF-B. We observed that cells overexpressing VEGF-B<sub>167</sub> gave rise to tumors that grow at similar kinetics as cells with endogenous VEGF-B levels. In contrast, tumors originated from cells with VEGF-B<sub>186</sub> overexpression grow significantly faster. These tumors have also an elevated capacity to recruit macrophages. In another tumor model, cells with *Vegfb* deletion attracted macrophages less efficiently to the tumor site compared to the cells with endogenous VEGF-B levels. However, the growth rate of the tumor xenografts in nude mice is similar. These findings indicate that VEGF-B is directly or indirectly involved in attracting macrophages to the tumor site. Tumor associated macrophages play an important role in promoting tumor progression, e.g. in the processes of neo-angiogenesis and/or immuno-suppression. The tumor promotion function of macrophages has also become a target for cancer therapy<sup>126</sup>. Blocking VEGF-B function by e.g. an antibody-based approach might interfere with the tumor promoting capacity of tumor associated macrophages.

Most cancer cells are known to predominantly produce energy by a high rate of glycolysis rather than oxidation of pyruvate in mitochondria as in most normal cells. This is known as the “Warburg Effect”, which helps promoting the fast-growth of cancer cells<sup>127-129</sup>. In Paper I, we have demonstrated a role of VEGF-B in FA uptake. In the cell, glucose and FA competes for substrates in metabolic processes, known as the Randle’s cycle<sup>75,76</sup> (described in Section 4.3.1). Taken all aforementioned knowledge together, it is not difficult to infer that VEGF-B can inhibit tumor growth by downregulation of glycolysis through inducing FA uptake. Careful selection of tumor models is crucial for testing this hypothesis due to the complex nature of metabolism in cancerous tissues.

## 5.2 The significance of our research


### 5.2.1 Is *VEGFB* a thrifty gene?

In *C. elegans*, a lower animal devoid of a vascular system, a family of four receptor tyrosine kinases that are structurally related to VEGFRs were identified<sup>130</sup>. This evolutionary legacy is a historical reproduction of the beginning of VEGFRs’ evolution. Although it is difficult to investigate the exact evolution paths of each individual VEGF, possible history of VEGF evolution can still be cautiously hypothesized based on a phylogenetic tree of VEGF/platelet-derived growth factors (PDGF) family members (Figure 8).



**Figure 8. Phylogenetic relationship among the human VEGF/PDGF family members generated with a multiple sequence alignment tool, Clustal Omega<sup>131</sup>.** Splice variants of VEGF-A, PIGF and VEGF-B are also shown.

Genome duplications, recombinations as well as genetic mutations create opportunities for speciation and evolution to occur, whereas natural selection pressures keep vital gene functions preserved. VEGF-B is highly conserved in mammals (Figure 9). This is an indication that VEGF-B has unique and important roles preserved under selection pressures. *VEGFB* promoter could be derived from a mismatched genome recombination which introduced regulatory elements from a mitochondrial gene. Further genome duplications and mutations could have separated VEGF-B from VEGF-A and PIGF early in the VEGF evolution history. At a certain time point, an ancient VEGF that had similar physiological function to the modern VEGF-B could have evolved, which allowed the organism to make better use of FA to match the respiratory oxidation capacity in the mitochondria. This evolutionary selective advantage could have kept mammalian VEGF-B highly conserved ever since.



**Figure 9, Homology analysis of mammalian VEGF-B genomic sequences by ECR browser<sup>132</sup>.** The two mRNA splice variants of human (*Homo sapiens*) VEGF-B are shown on the top. Percentage of sequence homology in each species compared to the human sequence is shown under. Only the ranges of 50% to 100% are shown. From top to bottom: opossum (*Monodelphis domestica*), rat (*Rattus norvegicus*), cow (*Bos taurus*), mouse (*Mus musculus*), dog (*Canis familiaris*), rhesus monkey (*Macaca mulatta*) and chimpanzee (*Pan troglodytes*). Blue: exon sequences; pink: intron sequences; green: repetitive sequences; yellow: sequences in untranslated regions.

Comparing to the evolution timeline of modern humans, easy food access, proper housing and clothing availability for the majority of people in the world has a relatively short history. For millions of years, evolution has favored the individuals with genes to store as much energy as possible in the preparation of temporary food shortages. Energy intake and expenditure for modern human beings have changed dramatically during the past a few hundreds, especially the past a few dozens of years. Relatively long reproductive cycle and life span have made human's evolution impossible to

catch up with the pace of changing life style. This phenomenon was well summarized in the early 1960s by Neel, who proposed the “thrifty gene hypothesis”<sup>133</sup>. *VEGFB*, hypothesized as a selection advantage throughout most of the mammalian evolutionary history, has now become an unwanted shortcoming that promotes metabolic disorders in modern humans. It is rational to hypothesize that *VEGFB* is one of the thrift genes that promotes lipid storage in heart and skeletal muscle as energy reservoirs.

### 5.2.2 Insulin resistance and adiposity

Adipose tissue exerts pivotal roles in energy storage and metabolism in animals. Obesity has become one of the prevailing health threats worldwide in modern societies. Severe forms of obesity are linked to reduced mobility, increased risks of metabolic syndrome, T2D, cardiovascular disease and other medical complications. These facts promoted the impression in the general public that the fat tissue is a “bad tissue”.

Lipodystrophy is a medical condition characterized by abnormal or degenerative conditions of the adipose tissue. Some forms of familial lipodystrophies are linked to deficiency in the genes that are crucial in adipocyte differentiation. Patients with these types of lipodystrophy usually have little or no adipose tissue in the body and develop severe hepatic steatosis and diabetes, since the excess lipid all goes to the liver and skeletal muscle. Without proper treatment, these patients hardly live through teen<sup>134,135</sup>. These findings showed strong evidences proving that adipose tissue is indispensable in whole-body fat metabolism.

In Paper I, we demonstrated an increased cardiac glucose uptake capacity despite an elevated body fat content in *Vegfb*<sup>-/-</sup> mice. In other words, when VEGF-B is absent, insulin sensitivity is decoupled with adiposity. This finding is in line with the hypothesis that ectopic muscular lipid accumulation, as a consequence of adiposity, but not excess body fat *per se*, is linked to the development of insulin resistance and diabetes<sup>136</sup>.

### 5.2.3 Current treatments for insulin resistance and T2D

Already in the early 20<sup>th</sup> century, regular exercise was proposed to be an important approach for managing T2D<sup>137</sup>. Increasing energy expenditure by exercising results in reduced muscular lipotoxicity, which in turn ameliorate insulin resistance in T2D<sup>136</sup>. Medical treatments need to be developed due to the difficulty of implementing life style interventions in patients.

Insulin has been used in treatment of diabetes for a relatively long period of time. Unlike insulin-synthesis/secretion-impaired type 1 diabetes, relatively large doses are necessary to overcome the insulin resistance in treatment of T2D. Insulin treatment is also known to induce weight gain and is associated with the risk of hypoglycemia<sup>138</sup>.

PPAR $\gamma$  is expressed predominantly in the adipose tissue and plays vital role in adipogenesis<sup>139</sup>. It is a ligand-dependent nuclear receptor that binds a variety of fatty

acids and lipid metabolites. The lipid-sensing nature of PPAR $\gamma$  has led to the development of synthetic PPAR $\gamma$  agonists as anti-diabetic drugs<sup>140,141</sup>. These compounds reduce plasma glucose and triglyceride levels, accompanied with a rise in high-density lipoprotein (HDL) cholesterol through activation of PPAR $\gamma$ <sup>140</sup>. One group of these compounds, thiazolidinediones (TZD), was shown to improve insulin sensitivity through reduction of intramyocellular diacylglycerol content<sup>142</sup>. Although once being a favored anti-diabetes drug, some of the TZD were revoked from the market due to side effects such as cardiac and hepatic complications<sup>138,143</sup>.

As of 2010, metformin (a biguanide) and glibenclamide (a sulfonylurea) are the only two oral antidiabetics in the World Health Organization Model List of Essential Medicines<sup>144</sup>. Metformin is the most commonly prescribed anti-diabetic drug worldwide. It improves hyperglycemia primarily by suppressing hepatic glucose production<sup>145</sup>. Glibenclamide, on the other hand, acts on pancreatic  $\beta$ -cells and stimulates insulin release. The combination oral administration of the two drugs was also proven to be more effective than monotherapy of either drug<sup>146</sup>.

Glucagon-like peptide-1 (GLP-1) belongs to a group of gastrointestinal hormones, the incretin hormone family. It is used as an anti-diabetic drug for its beneficial effects in blood glucose,  $\beta$ -cell function and insulin sensitivity. It is secreted upon the presence of nutrients in the lumen of the small intestine and stimulates insulin secretion in pancreatic  $\beta$ -cells through activation of G protein-coupled receptors<sup>147</sup>. GLP-1 has gastrointestinal side effects like nausea and diarrhea<sup>148</sup>. Not all patients receive GLP-1 can be expected to reach normoglycemia<sup>147</sup>.

#### **5.2.4 VEGF-B as the new therapeutic target**

The hypothesis that enhancing fat burning will reduce adiposity has led to studies on manipulations of FA oxidation<sup>149-152</sup>. However, a recent study has shown that acute or chronic upregulation of mitochondrial FA oxidation has no net effect on whole-body energy expenditure or adiposity<sup>153</sup>. Ironically, to some extent, this has already been predicted by Randle in 1960s<sup>75,76</sup>. The physiological balance of FA and glucose oxidation has made it difficult to achieve long-term metabolic benefits by altering only a few molecular pathways within the complex metabolic regulatory network.

Current treatments for T2D are mainly focused on reducing plasma glucose and triglyceride levels, as well as stimulate insulin secretion, without concentrating on the root of the disease, which is lipid-induced insulin resistance. Our studies of VEGF-B, however, indicate that manipulation of net energy input into the system by altering tissue FA uptake may be the effective way out for treating insulin resistance induced by muscular lipid accumulation. Combinations of the above mentioned therapies might become the “ultimate treatment” for metabolic disorders such as obesity, insulin resistance and T2D.



## 6 ACKNOWLEDGEMENTS

Note: some parts of the acknowledgements are written in my mother tongue with simplified English translations. People are acknowledged in the rough timely order of appearance.

首先感谢父母给了我生命。母亲培养了我对自然科学的兴趣，父亲教会了我健康的生活方式；祖父教我如何做人，祖母教我如何生活。尤其要感谢我刚刚过世的外祖父.....从小和您接触不多，但我清晰的记得大约两年前的那一面，记得您眼中散发的求知的光芒，记得您当时兴致勃勃的跟我大谈新近接触的全新工程技术。那一刻，我从来没有这么强烈的感受到我的身体里流淌着您的血液.....愿您在天堂安息。您将注视着我，见证您的生命在我身上延续.....

First I want to thank my parents, my father side grandparents, and especially mother's father, who passed away this summer...

我高中的班主任王向阳老师，您开明、平易近人。是您让我知道勤奋才是一个人成功的关键。I also want to thank my high school chemistry teacher.

Was it the summer of 2001 or 2002 when I first met you, **Hong**? You showed me around the lab and you were the reason why I started to become interested in this lab. For all these years, you are like an elder sister, a family, a friend. We talked about science, talked about life, among so many other things. And of course **Tao**, **Yihang** and **Julia**, there was always great food along with all the laughter at your place.

If I remember correctly, I first met you in the summer of 2003, **Ulf**. I came to Ludwig for an interview for doing the graduation project. I knew nothing about angiogenesis back then so I talked about how to use Photoshop and audio editing software to analyze data from animal physiology experiments, and even physics experiments. Surprisingly, you liked it, and it was where it all started. You are a truly different boss. You talk with us every day, have lunches with us. Not so many group leaders are usually this close to the lab members. We really, really appreciate this. There's one thing that I'll probably remember for my whole life. That's the talk we had after the dramatic change in my private life. Your attitude was totally unexpected: warm. Thank you for being very supportive when I was almost knocked down. I appreciate all the guidance from you, both in science and in life.

Then, I met the members in Ulf's lab at Ludwig. Firstly, **Christina Fieber**, thank you for being my first teacher in scientific research. I've done with you my first cell culture, first animal experiment, first PCR... **Linda**, **Annica Potén** and **Martin Lidén**, I learned a lot of basic lab techniques from you. **Erika**, thanks for lending me your office desk space without knowing. I think you were on a maternal leave when I came. I have to beat your Vasaloppet time some day! And **Martin**, there were the Laundry Test, Beijing Chicken, "dekstop", "shall we depart", a few minutes vs. several minutes... for some reason the only memory I have about the Ludwig kitchen is when you guys **Linda** and **Martin**, laughing together with me! We had lots of fun at the lunches. **Soheilla**, thank you for the always cheerful spirit! The small branch I got from you is now a really beautiful pot of plant. **Monika**, I first learned the word "humble" when **Martin** wrote about you in his thesis. I want to use it again now. We talked about lots of things ranging from plants to relationships, from politics to the universe. You should be on Facebook more often, not only on my birthday ;-). Hail all the **Uffe Puffe Groupe** spex we did and the doctoral hats we made! When it was the very first spex I participated, do you remember the question I asked "What is Persbrandt?" I still watch the DVD "Uffe Puffe Groupe Dissertation Parties '04-'06" every now and then. It was such great memories!

Thank you **Ralf Pettersson**, the former head of the Ludwig Stockholm Branch, and **Per Ljungdahl** for being my co-supervisor at the beginning of my PhD study.

**Annelie**, thank you for your always-appreciating smiles, the collaboration in the first paper and all the boosts to my projects for the manuscript! **Carolina**, I did my very first collaboration

with you. I learned a lot from it and I'm glad to be part of the Big Hit! **Daniel B**, you were a nice and quiet writing-desk neighbor and it was a pity that you couldn't stay longer. **Maarten**, we made the UEFS possible together! You seem to have a hobby as a job now, and that's so-called a dream-job, isn't it? **Joakim**, for some reason I didn't share any interests of computer games with you and that's weird... **Ingrid**, I should come to you for some running advance (or should I? ;-)) and maybe join some competitions in the future. **Lars M**, I'm still interested in your Metal music collection. I have a somewhat special compliment here: your personality (very, very nice) is conflicting with your visual appearance (Black Metal!). **Annika**, it was a great pleasure collaborating with you! Although there should still be a couple of years ahead of your PhD study, I'm already looking forward to see your thesis! Will it unveil the ultimate cure for diabetes? **Sebastian**, thank you for all the cakes, breads and cookies, as well as the interesting Polish-Sino documentary. **Hanna**, you have a great potential to become the next lab police for setting up the discipline and rules, and I think the lab needs it. **Sofia**, when doing GTT/ITT test with you in the animal facility, it feels that the time goes faster :-). Thank you for your great professional assistance with the animal works! **Daniel N**, if you keep your running plan, maybe we will bump into each other around the lake after I resume training. **Christine**, I still want to ask the question: "Do all Germans listen to Metal?" Listen to Metal and singing in a choir, an interesting German combination again. **Manuel** and **Philip**, welcome to our fantastic group! Over the years, group members changed and the lab even moved to another department, but the **Uffe Puffe Groupe** tradition of spex and hats stays!

**Kristian Pietras**, it feels really nice to have you as my co-supervisor starting from the middle of my PhD study. I didn't expect this coming when we shared a room at a conference back in 2006 though :-). I got lots of help and scientific guidance especially in animal-related techniques. **Lotta**, I hope we both find a satisfying career path, academic or not, in the future. **Marcela**, it was nice to have you as a neighbor in the office and thank you for the dinners at your place. **Sara C**, congratulations for the public defence application being granted! Good luck for the big day! **Pernilla**, it's nice to have you as the most positive energy in our office! **Eliane**, keep hard-working and it will definitely pay-off! **Annika P**, some people might miss your cakes more but I miss you more as an office neighbor, for all the not-so-often but refreshing and relaxing chats. It's a pity that you went back to the US before my defence. **Kristian H** and **Nick**, it sounds like a fantastic group for doing science, right? Welcome!

Special thanks to **Nick**, **Michal** and **Eliza** in Thomas Perlman's lab at Ludwig for all the great helps and discussions about transcription factors, luciferase assay and sharing the plasmids! And **Michal**, it was nice to have you briefly in our group at MBB before you moved to London.

The **Stenman's group**, **Minerva**, **Julianna**, **Chika**, **Belma**, **Mike**, **Karin** and **Lina**, I enjoyed the Bowling time with some of you as well as the discussion about the plate reader and real-time PCR!

All the previous and current Ludwig members: **Inger Tollman**, our great lab manager! It was always pleasant talking with you for your trip stories especially the ones in China! I'm glad to give you a ride with my Beetle! **Mats**, thank you for helping me to set up the file server after we moved to MBB. It won't be possible without your professional advice. **Maria B**, **Banafsheh**, **Idha**, **Magnus**, **Jamie**, **Nigel**, **Daniel H**, **Cécile**, and all the admins: **Erika Enrione**, **Eva Ramberg**, **Charlotta Linderholm** and **Birgitta Freidenfelt**, thank you all for the great scientific environment!

I want to thank all the collaborators outside of the lab, especially **Prof. Sharon Stone-Elander**. I still remember the gentle smile you always have on your face when I first listened to your lecture at a course back in 2005. It feels great that our labs started and continued the fruitful collaborations. Thank you for accepting Sisi for doing her master thesis and inviting me to co-supervise.

Group CBz: **Christer**, everyone remembers your funny song at Ying's dissertation party! There was also once you presented the aftermath of a U2 concert to explain a concept in vascular biology. I guess some great scientific ideas were inspired by your passion for music? **Ying 孙颖**, our MBB Chinese friends came together because of you! We really miss you and hope to see you more often next year. **Kazuhiro 萩仓一博**, it was nice to have a Japanese friend like you! **Lwaki**, thanks for all the discussions about relationships and marriage, especially the "Cow Theory". **Bàrbara**, I'll turn to you for more advice for making cocktails. **Colin**, don't work too much on night-shifts. A recent paper showed that glucagon secretion being messed up underlies the increased risk of insulin resistance in night-shift workers<sup>[citation needed]</sup>. **Linda**, it's so nice to see you back! **Jen**, Chinese and Americans do have common interests in space. Remember to share with me all the great news from NASA in the future. **Göran**, thank you for taking over the responsibilities for the microscope computers! And all the current and previous members: **Amrei**, **Annika A**, **Cecilia**, **Elisabeth R**, **Guillem**, **Hanyu 秦晗煜**, **Hélène**, **Johanna**, **Jong-Wook 洪鍾煜**, **Konstantin**, **Maarja**, **Maya**, **Radosa**, **Sara K**, **Tian 李甜** and **Tom**. Also the fairly newly founded Group Lars J: **Lars J**, **Yi 金义** and **Mikhail**.

Group JF: **Jonas**, **Joel** and **Tove**, you definitely win the price of highest running capacity per capita! **Mei-fong & Kah-Wai 彭美芳/凌嘉伟**, you are my best non-Chinese Chinese friends! Thank you for the dinners and sharing the passion for astronomy.

Group JB: **Johan Bjökegren**, thanks for doing the small exam required for my public defence application. **Ming-Mei 尚明美**, 感谢对我个人生活的关心 :-). It was a pity that we didn't talk more before you moved back to CMM. **Hassan**, it was great talks about computer science among other things at lunch! And also **Josefin** and **Husain**.

The Matrix Division of **Karl Tryggvason's group**, thank you for all the great parties together!

**Teresa**, **Hanna** and **Thomas** at the MBB animal facility, our research won't be possible without you! **Claudia**, thanks a lot for all the reagents, solutions, agars and autoclaves.

The previous and current admins at MBB: **Sarah L**, **Victoria**, **Jill B**, **Johanna S**, **Natalia**, **Anders L**, **Torbjörn**, **Svante**, **Jacek**. And of course **Chad**, the UEFS file server won't be a success without your help! I also enjoyed the discussions about the latest advances in hardware and software.

**Hugo Thelin**, it was a great honor to meet you. **Anders Larsson**, a retired Ericsson, a Vasaloppet veteran and my Vasaloppet tutor. Although I didn't touch my skis for the past a few winters, I've been keep training and I'm more fit than ever before! Another Vasaloppet is on my to-do list! **Kerstin & Raj Menon**, the lovely Indian couple who sold me the famous Yellow Beetle! I've never expected making friends by buying a car before.

My Chinese friends from the earliest years:

周莹、张文鑫、朱婕、吴永亮、孙晓乐、孔德国，我最早的一批中国朋友。这么多年了，有些变了，但是很多都没有变。学生生活总是觉得在飘，但是和你们在一块儿就有家的感觉。一起做饭，一起过年，一起闹，这不就是家人在一起做的事儿么？通过你们，我认识了：徐易轩、张子竹、朱鹏斐、常雨、杨思一/王夏涛、王菲、张家宁、刘金、杨柏、朱川黛西。通过王菲又认识了邓海荣、古剑、吴迪、季磊、程卓、周星雅、王宇，还有很多.....

雪婷，算了还是叫 Minerva 吧。09 年 2 月，我们组要搬到另一个系的前夕，你来到 Ludwig。感谢这几年的友谊。通过你，我认识了陈宁静和赵明，那回是在乾隆。从那次开始，我认识的朋友也越来越多.....

Counselor Zhang Ning and all the current and previous staff at the Education Section, Chinese Embassy to Sweden:

非常感谢大使馆教育处的张宁参赞，王炜、张宏两位老师，以及前任李旭东、范锐、卢春生老师。这些年

我参加了并且参与组织了不少教育处领导的活动，尤其是两次斯京春晚，娱乐了大家，锻炼了自己，感谢张参以及各位老师的栽培与照顾。

The Chinese Professors and Docents at the universities:

各所大学的学者老师和教授们：何颖芳/钟季存、胡立夫、李晋萍/张晓、郝景霞/徐晓军、沈志坚、徐志卿、崔大庆、祝捷、李楠/仇敏、Richard Hsieh。感谢老师们这么多年来对我学习和生活上的帮助。

Chinese friends at MBB: 程晴、郭婧、熊彦/金义、李甜、陆军、彭小小、秦哈煜、任晓远、孙嘉、唐筱、万敏、吴云飞、谢雪妹、徐萌、徐卫平/许建强、许茜、杨宏倩、张旭、张慧慧/杜亚涛、肖智婕/郑抗。谢谢许建强帮我修改了“科普综述”部分！

Chinese friends at KI & KS: 曹颖婷、畅征、马冉/陈新松、韩鸿雅、黄佳琦、李昱、楼婧华、石成蹊、石天晟、宋辞、宋建人、孙超、孙成君、王杰龄、王娜、汪奕昕、谢珊珊、胥婷、颜沁子、闫婕、赵斌、庄婷。

Sweden China Life Science Association/中瑞生命科学协会：窦丹/王皓、杨琼渊/高天乐、郝景霞、孙颖/贺立群、黄金灵、李慧洁、李思超、刘罡、宋志扬、王婧娇、严红梅/于江、詹晓/张韵、张寿庭、张晔。从入会之初就感受到一种实干的氛围，和大家一起共事既有成就感又开心！

Friends who did Chinese New Year Evening Galas together:

通过斯京春晚认识的朋友们：戴思扬（提手旁的扬）、邓岩、杜星龙、郝文明、璐璐、钟伟、李安琪、王海博、贾伟、欧阳湛、李思超、李超、梁柏荣、刘金、刘普正、黄锦、马占宇、牟望重、任佳美、孙刚、王皓、王路、王瑞熙萍、王尚宁、王思懿、王彦春、魏巍（SU）、邢勇涛、熊梓屹、许博/孙锲、徐柳、张雅玮、闫寒、杨怀宇、杨云凯、俞雯彬/尹博、Julie 于嘉瑞、翟师傅、张弛、张竣惟、张文、张元慧、赵晓林、郑佳、郑菁、郑沫、朱莹。《老歌新唱》、两届的相声、《非诚勿扰》、《夜来香》、《动漫联唱》、《西游新记》，另外还有那次华联办的卡拉OK比赛。特别是最能玩儿最能折腾的 Kungshamra 八卦阵成员，48 楼活动间排练的艰辛，演出的愉悦，无数的 party，无限的快乐！还有通过春晚的朋友们间接认识的曹源、窦艳、陆海、高石松、江深、李斌、浦梦溪、任无畏、王雅薇、野陆明、尹晓昕、马妍、张泽普，等等等等.....

还有唐婧，你就 miscellaneous 了，没有分类哈

早年 Kista 学联会主席章贞，感谢你对我职业发展的建议，和你交谈受益匪浅。

还有新近认识的一些朋友：Amy、王茜、马强、徐浩明、魏巍（中医医师）、Jason Tai、Cloe Zeng、Amelia Chong，好像都是通过婧娇和古剑认识的 :-)

Longtime friends from high school and university:

在欧洲碰面的大学和中学同学们：王璐、杨振林（不是“宁”）、冯珏、田浩；李玖莹、刘晶、程晓溪、舒晓。有缘能在国外相见不易啊。以及在国内最好的同学：吴辰、何鑫、牛洁。感谢带我从崩溃的边缘走了出来。

The most unforgettable trips with Chinese friends:

几次最难忘的旅行：09 和 10 年各一次 Gotland 之旅，10 和 11 年各一次圣诞滑雪，11 年 6 月初的欧洲婚纱摄影之旅，11 年 8 月的跳伞，以及 12 年 3 月的极光之旅。

## ONE MORE THING . . .

The title of this sub-chapter is a small tribute to Steve Jobs, former Apple CEO, for his characteristic and usually entertaining “one more thing...” sections in Stevenotes.

Quoting from his famous speech at Stanford University in 2005:  
“You’ve got to find what you love”; “Stay hungry, stay foolish”.

Although it is obvious to some readers, I should still emphasize that this sub-chapter is NOT a scientific manuscript. This is special thanks for the people who made it possible and documentation for what have been done.

## Data security and network communications in an academic research environment

Xun Wang<sup>\*,#</sup>, Chad Tunell<sup>\*</sup>, Maarten Vanwildemeersch<sup>\*,#</sup>, Mats Anderling<sup>#</sup> and Ulf Eriksson<sup>\*,#</sup>

<sup>\*</sup>Tissue Biology Group, Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.

<sup>#</sup>Ludwig Institute for Cancer Research Ltd, Stockholm Branch, Karolinska Institutet, Box 240, SE-171 77 Stockholm, Sweden.

There are three inevitable things in life: tax, death and hard drive failure.

We’ve built a file and mailing list server. It’s based on a Mac Mini early 2009 model with OS X Lion Server 10.7.5. An external hard drive is used for primary data storage. The data and boot drive are both daily and incrementally backed up to a Drobo 2 Gen disk array using Time Machine for multi-level data redundancy. The headless server is managed remotely through native VNC support by Mac OS X. All the network communication ports are open to the local department ethernet while KI-VPN connection must be established if accessing from outside of the department.

The file server supports AFP for Macs and SMB for Windows PCs. AFP works seamlessly with Mac computers. But since Apple has replaced SMB with an in-house version of SMBX starting in Lion due to changes in SMB licencing, SMB support for Windows-based computers became poor. The Offline Files function under various versions of Windows became incompatible after upgrading to Lion from Snow Leopard. It is probably due to the changes in Oplocks capability in SMBX. SMB authentication became slower as well. These changes cause problems with opening and saving Microsoft Office and Adobe PDF files. A quick trial under Mountain Lion indicates that the kernel codes of SMBX haven’t been improved to fix the aforementioned bugs.

Each user has his/her own user account and folder with full accessibility. A user can only read data from other users in the same group, while there’s no data accessibility across the groups. A common guest account and temporary folders are also available for easy data exchange.

The mailing list server is based on a series of Gmail addresses and the default Mail program in Lion. An email is sent to a Gmail address, the Mail program will then redirect, rather than forward, according to a set of rules to the corresponding recipients. There is a master address for sending to all the research groups. This address points to the addresses for each group, and then the each group address points to individual recipients. The user addresses and groups are maintained using Address Book in Lion. A combination of groups or specialized groups of addresses like “Cell Culture” or “Starget” was realized by setting up corresponding rules in Mail.

## 7 REFERENCES

1. Tammela, T., Enholm, B., Alitalo, K. & Paavonen, K. The biology of vascular endothelial growth factors. *Cardiovasc Res* **65**, 550-563 (2005).
2. Otrock, Z.K., Makarem, J.A. & Shamseddine, A.I. Vascular endothelial growth factor family of ligands and receptors: review. *Blood cells, molecules & diseases* **38**, 258-268 (2007).
3. Li, X. & Eriksson, U. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. *The international journal of biochemistry & cell biology* **33**, 421-426 (2001).
4. Senger, D.R., *et al.* Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. *Science* **219**, 983-985 (1983).
5. Carmeliet, P., *et al.* Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. *Nature* **380**, 435-439 (1996).
6. Shweiki, D., Itin, A., Soffer, D. & Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. *Nature* **359**, 843-845 (1992).
7. Liu, Y., Cox, S.R., Morita, T. & Kourembanas, S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. *Circ Res* **77**, 638-643 (1995).
8. Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P. & Persico, M.G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. *Proc Natl Acad Sci U S A* **88**, 9267-9271 (1991).
9. Persico, M.G., Vincenti, V. & DiPalma, T. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). *Current topics in microbiology and immunology* **237**, 31-40 (1999).
10. Carmeliet, P., *et al.* Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. *Nat Med* **7**, 575-583 (2001).
11. Oura, H., *et al.* A critical role of placental growth factor in the induction of inflammation and edema formation. *Blood* **101**, 560-567 (2003).
12. Odorisio, T., *et al.* Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. *Journal of cell science* **115**, 2559-2567 (2002).
13. Olofsson, B., *et al.* Vascular endothelial growth factor B, a novel growth factor for endothelial cells. *Proc Natl Acad Sci U S A* **93**, 2576-2581 (1996).
14. Ferrara, N., Gerber, H.P. & LeCouter, J. The biology of VEGF and its receptors. *Nat Med* **9**, 669-676 (2003).
15. Gerber, H.P., Condorelli, F., Park, J. & Ferrara, N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. *J Biol Chem* **272**, 23659-23667 (1997).
16. Autiero, M., *et al.* Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. *Nat Med* **9**, 936-943 (2003).
17. Arany, Z., *et al.* HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1 $\alpha$ . *Nature* **451**, 1008-1012 (2008).

18. Stein, R.A., Gaillard, S. & McDonnell, D.P. Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells. *J Steroid Biochem Mol Biol* **114**, 106-112 (2009).
19. Xue, Y., *et al.* Hypoxia-independent angiogenesis in adipose tissues during cold acclimation. *Cell Metab* **9**, 99-109 (2009).
20. Zhang, K., *et al.* Baicalin increases VEGF expression and angiogenesis by activating the ERR{alpha}/PGC-1{alpha} pathway. *Cardiovasc Res* **89**, 426-435 (2011).
21. Breier, G., Clauss, M. & Risau, W. Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development. *Dev Dyn* **204**, 228-239 (1995).
22. Jakobsson, L., *et al.* Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. *Nature cell biology* **12**, 943-953 (2010).
23. Lahteenvuori, J.E., *et al.* Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms. *Circulation* **119**, 845-856 (2009).
24. Gille, H., *et al.* Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. *J Biol Chem* **276**, 3222-3230 (2001).
25. Kearney, J.B., Kappas, N.C., Ellerstrom, C., DiPaola, F.W. & Bautch, V.L. The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. *Blood* **103**, 4527-4535 (2004).
26. Fong, G.H., Rossant, J., Gertsenstein, M. & Breitman, M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. *Nature* **376**, 66-70 (1995).
27. Hiratsuka, S., Minowa, O., Kuno, J., Noda, T. & Shibuya, M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. *Proc Natl Acad Sci U S A* **95**, 9349-9354 (1998).
28. Park, J.E., Chen, H.H., Winer, J., Houck, K.A. & Ferrara, N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. *J Biol Chem* **269**, 25646-25654 (1994).
29. Kendall, R.L. & Thomas, K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. *Proc Natl Acad Sci U S A* **90**, 10705-10709 (1993).
30. Maynard, S.E., Venkatesha, S., Thadhani, R. & Karumanchi, S.A. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. *Pediatric research* **57**, 1R-7R (2005).
31. Kolodkin, A.L., *et al.* Neuropilin is a semaphorin III receptor. *Cell* **90**, 753-762 (1997).
32. He, Z. & Tessier-Lavigne, M. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. *Cell* **90**, 739-751 (1997).
33. Chen, H., Chedotal, A., He, Z., Goodman, C.S. & Tessier-Lavigne, M. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. *Neuron* **19**, 547-559 (1997).
34. Klagsbrun, M., Takashima, S. & Mamluk, R. The role of neuropilin in vascular and tumor biology. *Advances in experimental medicine and biology* **515**, 33-48 (2002).

35. Soker, S., Takashima, S., Miao, H.Q., Neufeld, G. & Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. *Cell* **92**, 735-745 (1998).
36. Neufeld, G., *et al.* The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. *Trends in cardiovascular medicine* **12**, 13-19 (2002).
37. Cai, H. & Reed, R.R. Cloning and characterization of neuropilin-1-interacting protein: a PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **19**, 6519-6527 (1999).
38. Wang, L., Zeng, H., Wang, P., Soker, S. & Mukhopadhyay, D. Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. *J Biol Chem* **278**, 48848-48860 (2003).
39. Kawasaki, T., *et al.* A requirement for neuropilin-1 in embryonic vessel formation. *Development* **126**, 4895-4902 (1999).
40. Grunewald, F.S., Prota, A.E., Giese, A. & Ballmer-Hofer, K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. *Biochimica et biophysica acta* **1804**, 567-580 (2010).
41. Olofsson, B., *et al.* Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. *J Biol Chem* **271**, 19310-19317 (1996).
42. Karkkainen, M.J., *et al.* Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. *Nature immunology* **5**, 74-80 (2004).
43. Haiko, P., *et al.* Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. *Mol Cell Biol* **28**, 4843-4850 (2008).
44. Lyttle, D.J., Fraser, K.M., Fleming, S.B., Mercer, A.A. & Robinson, A.J. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. *Journal of virology* **68**, 84-92 (1994).
45. Yamazaki, Y., Tokunaga, Y., Takani, K. & Morita, T. Identification of the heparin-binding region of snake venom vascular endothelial growth factor (VEGF-F) and its blocking of VEGF-A165. *Biochemistry* **44**, 8858-8864 (2005).
46. Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. *Science* **246**, 1306-1309 (1989).
47. Bellomo, D., *et al.* Mice lacking the vascular endothelial growth factor-B gene (*Vegfb*) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. *Circ Res* **86**, E29-35 (2000).
48. Aase, K., *et al.* Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. *Circulation* **104**, 358-364 (2001).
49. Hagberg, C.E., *et al.* Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. *Nature advance online publication*(2012).
50. Joukov, V., *et al.* A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. *The EMBO journal* **15**, 1751 (1996).



51. Orlandini, M., Marconcini, L., Ferruzzi, R. & Oliviero, S. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. *Proc Natl Acad Sci U S A* **93**, 11675-11680 (1996).
52. Baldwin, M.E., *et al.* Vascular endothelial growth factor D is dispensable for development of the lymphatic system. *Mol Cell Biol* **25**, 2441-2449 (2005).
53. Ogawa, S., *et al.* A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. *J Biol Chem* **273**, 31273-31282 (1998).
54. Olofsson, B., *et al.* Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. *Proc Natl Acad Sci U S A* **95**, 11709-11714 (1998).
55. Li, X., Aase, K., Li, H., von Euler, G. & Eriksson, U. Isoform-specific expression of VEGF-B in normal tissues and tumors. *Growth factors* **19**, 49-59 (2001).
56. Li, X., *et al.* Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. *Arterioscler Thromb Vasc Biol* **28**, 1614-1620 (2008).
57. Enholm, B., *et al.* Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. *Oncogene* **14**, 2475-2483 (1997).
58. Wright, C.E. Effects of vascular endothelial growth factor (VEGF)A and VEGFB gene transfer on vascular reserve in a conscious rabbit hindlimb ischaemia model. *Clinical and experimental pharmacology & physiology* **29**, 1035-1039 (2002).
59. Sun, Y., *et al.* Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: evidence from knockout mice and growth factor administration. *Developmental biology* **289**, 329-335 (2006).
60. Falk, T., *et al.* Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease. *Neuroscience letters* **496**, 43-47 (2011).
61. Poesen, K., *et al.* Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **28**, 10451-10459 (2008).
62. Sun, Y., *et al.* Increased severity of cerebral ischemic injury in vascular endothelial growth factor-B-deficient mice. *J Cereb Blood Flow Metab* **24**, 1146-1152 (2004).
63. Li, Y., *et al.* VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. *J Clin Invest* **118**, 913-923 (2008).
64. Karpanen, T., *et al.* Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. *Circ Res* **103**, 1018-1026 (2008).
65. Stahl, A. A current review of fatty acid transport proteins (SLC27). *Pflugers Archiv : European journal of physiology* **447**, 722-727 (2004).
66. van der Vusse, G.J., van Bilsen, M. & Glatz, J.F. Cardiac fatty acid uptake and transport in health and disease. *Cardiovasc Res* **45**, 279-293 (2000).
67. Jia, Z., Pei, Z., Maignel, D., Toomer, C.J. & Watkins, P.A. The fatty acid transport protein (FATP) family: very long chain acyl-CoA synthetases or solute carriers? *Journal of molecular neuroscience : MN* **33**, 25-31 (2007).

68. Abumrad, N.A., el-Maghrabi, M.R., Amri, E.Z., Lopez, E. & Grimaldi, P.A. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. *J Biol Chem* **268**, 17665-17668 (1993).
69. Coburn, C.T., Hajri, T., Ibrahimi, A. & Abumrad, N.A. Role of CD36 in membrane transport and utilization of long-chain fatty acids by different tissues. *Journal of molecular neuroscience : MN* **16**, 117-121; discussion 151-117 (2001).
70. Skalak, T.C. Angiogenesis and microvascular remodeling: a brief history and future roadmap. *Microcirculation* **12**, 47-58 (2005).
71. Greenblatt, M. & Shubi, P. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. *Journal of the National Cancer Institute* **41**, 111-124 (1968).
72. Folkman, J. Tumor angiogenesis: therapeutic implications. *The New England journal of medicine* **285**, 1182-1186 (1971).
73. Ellis, L.M. & Hicklin, D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. *Nat Rev Cancer* **8**, 579-591 (2008).
74. Agre, P. The aquaporin water channels. *Proceedings of the American Thoracic Society* **3**, 5-13 (2006).
75. Randle, P.J., Garland, P.B., Hales, C.N. & Newsholme, E.A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. *Lancet* **1**, 785-789 (1963).
76. Randle, P.J. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. *Diabetes/metabolism reviews* **14**, 263-283 (1998).
77. Savage, D.B., Petersen, K.F. & Shulman, G.I. Disordered lipid metabolism and the pathogenesis of insulin resistance. *Physiol Rev* **87**, 507-520 (2007).
78. Petersen, K.F. & Shulman, G.I. Cellular mechanism of insulin resistance in skeletal muscle. *J R Soc Med* **95 Suppl 42**, 8-13 (2002).
79. Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. *Endocr Rev* **25**, 581-611 (2004).
80. Fischer, C., Mazzone, M., Jonckx, B. & Carmeliet, P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? *Nat Rev Cancer* **8**, 942-956 (2008).
81. Ristimaki, A., Narko, K., Enholm, B., Joukov, V. & Alitalo, K. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. *J Biol Chem* **273**, 8413-8418 (1998).
82. Chilov, D., *et al.* Genomic organization of human and mouse genes for vascular endothelial growth factor C. *J Biol Chem* **272**, 25176-25183 (1997).
83. Keen, H.L., *et al.* Gene expression profiling of potential PPARgamma target genes in mouse aorta. *Physiol Genomics* **18**, 33-42 (2004).
84. Kivela, R., *et al.* Effects of experimental type 1 diabetes and exercise training on angiogenic gene expression and capillarization in skeletal muscle. *FASEB J* **20**, 1570-1572 (2006).
85. Yamamoto, H., *et al.* NCoR1 is a conserved physiological modulator of muscle mass and oxidative function. *Cell* **147**, 827-839 (2011).

86. Bostrom, P., *et al.* A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. *Nature* **481**, 463-468 (2012).
87. Tadaishi, M., *et al.* Skeletal muscle-specific expression of PGC-1alpha-b, an exercise-responsive isoform, increases exercise capacity and peak oxygen uptake. *PloS one* **6**, e28290 (2011).
88. Villena, J.A. & Kralli, A. ERRalpha: a metabolic function for the oldest orphan. *Trends Endocrinol Metab* **19**, 269-276 (2008).
89. Lin, J., *et al.* Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. *Nature* **418**, 797-801 (2002).
90. Arany, Z. PGC-1 coactivators and skeletal muscle adaptations in health and disease. *Curr Opin Genet Dev* **18**, 426-434 (2008).
91. Vega, R.B., Huss, J.M. & Kelly, D.P. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. *Mol Cell Biol* **20**, 1868-1876 (2000).
92. Alaynick, W.A. Nuclear receptors, mitochondria and lipid metabolism. *Mitochondrion* **8**, 329-337 (2008).
93. Scarpulla, R.C. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. *Physiol Rev* **88**, 611-638 (2008).
94. Finck, B.N. & Kelly, D.P. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. *J Clin Invest* **116**, 615-622 (2006).
95. Liang, H. & Ward, W.F. PGC-1alpha: a key regulator of energy metabolism. *Adv Physiol Educ* **30**, 145-151 (2006).
96. Puigserver, P. & Spiegelman, B.M. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. *Endocr Rev* **24**, 78-90 (2003).
97. Knutti, D. & Kralli, A. PGC-1, a versatile coactivator. *Trends Endocrinol Metab* **12**, 360-365 (2001).
98. Baar, K. Involvement of PPAR gamma co-activator-1, nuclear respiratory factors 1 and 2, and PPAR alpha in the adaptive response to endurance exercise. *Proc Nutr Soc* **63**, 269-273 (2004).
99. Nisoli, E., *et al.* Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. *Science* **299**, 896-899 (2003).
100. Sladek, R., Bader, J.A. & Giguere, V. The orphan nuclear receptor estrogen-related receptor alpha is a transcriptional regulator of the human medium-chain acyl coenzyme A dehydrogenase gene. *Mol Cell Biol* **17**, 5400-5409 (1997).
101. Castet, A., *et al.* Receptor-interacting protein 140 differentially regulates estrogen receptor-related receptor transactivation depending on target genes. *Mol Endocrinol* **20**, 1035-1047 (2006).
102. Sumi, D. & Ignarro, L.J. Sp1 transcription factor expression is regulated by estrogen-related receptor alpha1. *Biochem Biophys Res Commun* **328**, 165-172 (2005).
103. Huss, J.M., Torra, I.P., Staels, B., Giguere, V. & Kelly, D.P. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. *Mol Cell Biol* **24**, 9079-9091 (2004).

104. Gustafsson, T., Puntchart, A., Kaijser, L., Jansson, E. & Sundberg, C.J. Exercise-induced expression of angiogenesis-related transcription and growth factors in human skeletal muscle. *Am J Physiol* **276**, H679-685 (1999).
105. Richardson, R.S., *et al.* Human VEGF gene expression in skeletal muscle: effect of acute normoxic and hypoxic exercise. *Am J Physiol* **277**, H2247-2252 (1999).
106. Breen, E.C., *et al.* Angiogenic growth factor mRNA responses in muscle to a single bout of exercise. *J Appl Physiol* **81**, 355-361 (1996).
107. Samuel, V.T., Petersen, K.F. & Shulman, G.I. Lipid-induced insulin resistance: unravelling the mechanism. *Lancet* **375**, 2267-2277 (2010).
108. Shepherd, P.R. & Kahn, B.B. Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus. *The New England journal of medicine* **341**, 248-257 (1999).
109. Ciaraldi, T.P., Abrams, L., Nikoulina, S., Mudaliar, S. & Henry, R.R. Glucose transport in cultured human skeletal muscle cells. Regulation by insulin and glucose in nondiabetic and non-insulin-dependent diabetes mellitus subjects. *J Clin Invest* **96**, 2820-2827 (1995).
110. Torres-Leal, F.L., Fonseca-Alaniz, M.H., Rogero, M.M. & Tirapegui, J. The role of inflamed adipose tissue in the insulin resistance. *Cell biochemistry and function* **28**, 623-631 (2010).
111. Bostrom, P., *et al.* The SNARE protein SNAP23 and the SNARE-interacting protein Munc18c in human skeletal muscle are implicated in insulin resistance/type 2 diabetes. *Diabetes* **59**, 1870-1878 (2010).
112. Choi, C.S., *et al.* Paradoxical effects of increased expression of PGC-1alpha on muscle mitochondrial function and insulin-stimulated muscle glucose metabolism. *Proc Natl Acad Sci U S A* **105**, 19926-19931 (2008).
113. Mills, J.C., *et al.* A molecular profile of the mouse gastric parietal cell with and without exposure to *Helicobacter pylori*. *Proc Natl Acad Sci U S A* **98**, 13687-13692 (2001).
114. Capoccia, B.J., Huh, W.J. & Mills, J.C. How form follows functional genomics: gene expression profiling gastric epithelial cells with a particular discourse on the parietal cell. *Physiol Genomics* **37**, 67-78 (2009).
115. Konturek, J.W., Bielanski, W., Konturek, S.J. & Domschke, W. Eradication of *Helicobacter pylori* and gastrin-somatostatin link in duodenal ulcer patients. *Journal of physiology and pharmacology : an official journal of the Polish Physiological Society* **47**, 161-175 (1996).
116. Ohata, H., *et al.* Progression of chronic atrophic gastritis associated with *Helicobacter pylori* infection increases risk of gastric cancer. *International journal of cancer. Journal international du cancer* **109**, 138-143 (2004).
117. Kim, K.J., *et al.* Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. *Nature* **362**, 841-844 (1993).
118. Wei, S.C., *et al.* Placenta growth factor expression is correlated with survival of patients with colorectal cancer. *Gut* **54**, 666-672 (2005).
119. Dalal, S., *et al.* Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. *Clinical cancer research : an official journal of the American Association for Cancer Research* **11**, 2364-2378 (2005).
120. Fischer, C., *et al.* Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. *Cell* **131**, 463-475 (2007).

121. Van de Veire, S., *et al.* Further pharmacological and genetic evidence for the efficacy of PIGF inhibition in cancer and eye disease. *Cell* **141**, 178-190 (2010).
122. Luttun, A., Tjwa, M. & Carmeliet, P. Placental growth factor (PIGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. *Ann N Y Acad Sci* **979**, 80-93 (2002).
123. Bais, C., *et al.* PIGF blockade does not inhibit angiogenesis during primary tumor growth. *Cell* **141**, 166-177 (2010).
124. Verrax, J., *et al.* Delivery of soluble VEGF receptor 1 (sFlt1) by gene electrotransfer as a new antiangiogenic cancer therapy. *Molecular pharmaceutics* **8**, 701-708 (2011).
125. Albrecht, I., *et al.* Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. *PloS one* **5**, e14109 (2010).
126. Ruffell, B., Affara, N.I. & Coussens, L.M. Differential macrophage programming in the tumor microenvironment. *Trends in immunology* **33**, 119-126 (2012).
127. Warburg, O. On the origin of cancer cells. *Science* **123**, 309-314 (1956).
128. Gatenby, R.A. & Gillies, R.J. Why do cancers have high aerobic glycolysis? *Nat Rev Cancer* **4**, 891-899 (2004).
129. Kim, J.W. & Dang, C.V. Cancer's molecular sweet tooth and the Warburg effect. *Cancer research* **66**, 8927-8930 (2006).
130. Popovici, C., Isnardon, D., Birnbaum, D. & Roubin, R. Caenorhabditis elegans receptors related to mammalian vascular endothelial growth factor receptors are expressed in neural cells. *Neuroscience letters* **329**, 116-120 (2002).
131. Sievers, F., *et al.* Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Molecular systems biology* **7**, 539 (2011).
132. Ovcharenko, I., Nobrega, M.A., Loots, G.G. & Stubbs, L. ECR Browser: a tool for visualizing and accessing data from comparisons of multiple vertebrate genomes. *Nucleic Acids Res* **32**, W280-286 (2004).
133. Neel, J.V. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? *American journal of human genetics* **14**, 353-362 (1962).
134. Capeau, J., *et al.* Human lipodystrophies: genetic and acquired diseases of adipose tissue. *Endocrine development* **19**, 1-20 (2010).
135. Garg, A. Lipodystrophies. *The American journal of medicine* **108**, 143-152 (2000).
136. Chow, L., From, A. & Seaquist, E. Skeletal muscle insulin resistance: the interplay of local lipid excess and mitochondrial dysfunction. *Metabolism: clinical and experimental* **59**, 70-85 (2010).
137. Schneider, S.H. & Ruderman, N.B. Exercise and physical training in the treatment of diabetes mellitus. *Comprehensive therapy* **12**, 49-56 (1986).
138. Mazzola, N. Review of current and emerging therapies in type 2 diabetes mellitus. *The American journal of managed care* **18**, S17-26 (2012).
139. Ren, D., Collingwood, T.N., Rebar, E.J., Wolffe, A.P. & Camp, H.S. PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. *Genes & development* **16**, 27-32 (2002).

140. Willson, T.M., Lambert, M.H. & Kliewer, S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. *Annual review of biochemistry* **70**, 341-367 (2001).
141. Ibrahimi, A., *et al.* Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. *Molecular pharmacology* **46**, 1070-1076 (1994).
142. Mayerson, A.B., *et al.* The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. *Diabetes* **51**, 797-802 (2002).
143. Larsen, T.M., Toubro, S. & Astrup, A. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? *International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity* **27**, 147-161 (2003).
144. Lindenberg, M., Kopp, S. & Dressman, J.B. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. *European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V* **58**, 265-278 (2004).
145. Kirpichnikov, D., McFarlane, S.I. & Sowers, J.R. Metformin: an update. *Annals of internal medicine* **137**, 25-33 (2002).
146. Davidson, J.A., Scheen, A.J. & Howlett, H.C. Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus. *Drug safety : an international journal of medical toxicology and drug experience* **27**, 1205-1216 (2004).
147. Toft-Nielsen, M.B., Madsbad, S. & Holst, J.J. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. *The Journal of clinical endocrinology and metabolism* **86**, 3853-3860 (2001).
148. Barnett, A.H. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. *Diabetes Obes Metab* **14**, 304-314 (2012).
149. Lage, R., Dieguez, C., Vidal-Puig, A. & Lopez, M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. *Trends in molecular medicine* **14**, 539-549 (2008).
150. Narkar, V.A., *et al.* AMPK and PPARdelta agonists are exercise mimetics. *Cell* **134**, 405-415 (2008).
151. Choi, C.S., *et al.* Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. *Proc Natl Acad Sci U S A* **104**, 16480-16485 (2007).
152. Abu-Elheiga, L., Matzuk, M.M., Abo-Hashema, K.A. & Wakil, S.J. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. *Science* **291**, 2613-2616 (2001).
153. Hoehn, K.L., *et al.* Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity. *Cell Metab* **11**, 70-76 (2010).